{"id":30657,"date":"2026-05-15T23:23:55","date_gmt":"2026-05-15T23:23:55","guid":{"rendered":"https:\/\/www.othellointernational.com\/?page_id=30657"},"modified":"2026-06-27T08:19:06","modified_gmt":"2026-06-27T08:19:06","slug":"healthcare-pharma","status":"publish","type":"page","link":"https:\/\/www.othellointernational.com\/th\/healthcare-pharma\/","title":{"rendered":"\u0e2a\u0e38\u0e02\u0e20\u0e32\u0e1e\u0e41\u0e25\u0e30\u0e40\u0e20\u0e2a\u0e31\u0e0a\u0e01\u0e23\u0e23\u0e21"},"content":{"rendered":"\n<div class=\"oth-hp\">\n<style>\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Poppins:wght@300;400;500;600;700;800;900&family=Fraunces:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600&family=JetBrains+Mono:wght@400;500;600;700&family=Sarabun:wght@400;500;600&display=swap');\n\n.oth-hp{\n  --black:#000;--black-soft:#0a0a0a;--black-elev:#141414;--black-card:#1a1a1a;--black-line:#2a2a2a;\n  --red:#ED4036;--red-bright:#FF5046;--red-deep:#C2261C;--red-dark:#8a1a13;\n  --white:#fff;--white-soft:rgba(255,255,255,0.78);--white-mute:rgba(255,255,255,0.62);--white-dim:rgba(255,255,255,0.50);--white-line:rgba(255,255,255,0.12);\n  --green:#4ade80;--amber:#fbbf24;--blue:#60a5fa;--teal:#2dd4bf;--purple:#a78bfa;\n  --font-sans:'Poppins',-apple-system,BlinkMacSystemFont,sans-serif;\n  --font-display:'Fraunces',Georgia,serif;\n  --font-mono:'JetBrains Mono',Menlo,monospace;\n  --font-thai:'Sarabun',sans-serif;\n  background:var(--black);color:var(--white);font-family:var(--font-sans);font-weight:400;line-height:1.65;\n  scroll-padding-top:76px;\n}\n.oth-hp *,.oth-hp *::before,.oth-hp *::after{box-sizing:border-box;margin:0;padding:0}\n.oth-hp html{scroll-behavior:smooth}\n.oth-hp a{color:inherit;text-decoration:none}\n.oth-hp a:focus-visible,.oth-hp button:focus-visible,.oth-hp summary:focus-visible{outline:2px solid var(--red-bright);outline-offset:3px;border-radius:4px}\n.oth-hp img,.oth-hp svg{max-width:100%;display:block}\n.oth-hp ::selection{background:var(--red);color:var(--white)}\n.oth-hp .read-progress{position:fixed;top:0;left:0;height:3px;width:0;background:linear-gradient(90deg,var(--red-deep),var(--red-bright));z-index:9999;transition:width 0.1s linear}\n.oth-hp .status-strip{background:var(--black-soft);border-bottom:1px solid var(--black-line);padding:10px 0;font-family:var(--font-mono);font-size:11px;font-weight:500;letter-spacing:0.08em;text-transform:uppercase;color:var(--white-mute)}\n.oth-hp .status-inner{max-width:1280px;margin:0 auto;padding:0 24px;display:flex;justify-content:space-between;flex-wrap:wrap;gap:12px;align-items:center}\n.oth-hp .status-left{display:flex;align-items:center;gap:14px;flex-wrap:wrap}\n.oth-hp .status-dot{width:7px;height:7px;border-radius:50%;background:var(--green);box-shadow:0 0 8px var(--green);animation:pulsehp 2s ease-in-out infinite}\n@keyframes pulsehp{0%,100%{opacity:1}50%{opacity:.45}}\n.oth-hp .status-pill{display:inline-flex;align-items:center;gap:6px;padding:4px 10px;border:1px solid var(--black-line);border-radius:999px;color:var(--white-soft)}\n.oth-hp .crumb{background:var(--black);border-bottom:1px solid var(--black-line);padding:14px 0;font-family:var(--font-mono);font-size:11px;letter-spacing:0.06em;color:var(--white-dim)}\n.oth-hp .crumb-inner{max-width:1280px;margin:0 auto;padding:0 24px;display:flex;align-items:center;gap:10px;flex-wrap:wrap}\n.oth-hp .crumb a{color:var(--white-mute);transition:color .2s}\n.oth-hp .crumb a:hover{color:var(--red-bright)}\n.oth-hp .crumb-sep{opacity:.4}\n.oth-hp .crumb-current{color:var(--red-bright);font-weight:600}\n.oth-hp .sticky-nav{position:fixed;top:18px;left:50%;transform:translateX(-50%) translateY(-150%);z-index:200;background:rgba(20,20,20,0.92);backdrop-filter:blur(20px);-webkit-backdrop-filter:blur(20px);border:1px solid var(--white-line);border-radius:999px;padding:8px 8px 8px 18px;display:flex;align-items:center;gap:14px;transition:transform .35s cubic-bezier(.2,.7,.2,1);max-width:calc(100vw - 32px);overflow-x:auto;scrollbar-width:none}\n.oth-hp .sticky-nav::-webkit-scrollbar{display:none}\n.oth-hp .sticky-nav.visible{transform:translateX(-50%) translateY(0)}\n.oth-hp .sticky-nav-label{font-family:var(--font-mono);font-size:10px;letter-spacing:0.1em;text-transform:uppercase;color:var(--white-mute);white-space:nowrap}\n.oth-hp .sticky-nav-links{display:flex;align-items:center;gap:4px}\n.oth-hp .sticky-nav-links a{font-family:var(--font-mono);font-size:10.5px;letter-spacing:0.08em;text-transform:uppercase;color:var(--white-soft);padding:8px 12px;border-radius:999px;transition:all .2s;white-space:nowrap}\n.oth-hp .sticky-nav-links a:hover{color:var(--white);background:var(--black-line)}\n.oth-hp .sticky-nav-links a.active{color:var(--white);background:var(--red);box-shadow:0 4px 12px rgba(237,64,54,.4)}\n.oth-hp .sticky-nav-cta{font-family:var(--font-mono);font-size:10.5px;letter-spacing:0.08em;text-transform:uppercase;background:var(--red);color:var(--white);padding:8px 14px;border-radius:999px;font-weight:600;transition:background .2s}\n.oth-hp .sticky-nav-cta:hover{background:var(--red-bright)}\n.oth-hp .float-cta{display:none;position:fixed;bottom:20px;right:20px;z-index:300;background:var(--red);color:var(--white);padding:14px 22px;border-radius:999px;font-family:var(--font-mono);font-size:12px;font-weight:700;letter-spacing:0.08em;text-transform:uppercase;box-shadow:0 8px 30px rgba(237,64,54,.5),0 0 0 1px rgba(255,255,255,.1);transition:all .2s}\n.oth-hp .float-cta:hover{background:var(--red-bright);transform:translateY(-2px)}\n.oth-hp .container{max-width:1280px;margin:0 auto;padding:0 24px}\n.oth-hp section{padding:88px 0;border-bottom:1px solid var(--black-line);position:relative}\n.oth-hp section:nth-child(even){background:var(--black-soft)}\n.oth-hp .eyebrow{display:inline-flex;align-items:center;gap:10px;font-family:var(--font-mono);font-size:11px;font-weight:600;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);margin-bottom:18px}\n.oth-hp .eyebrow::before{content:\"\";width:24px;height:1px;background:var(--red)}\n.oth-hp h2.section-h{font-family:var(--font-sans);font-size:clamp(28px,4vw,46px);font-weight:700;line-height:1.12;letter-spacing:-0.02em;margin-bottom:18px;color:var(--white)}\n.oth-hp h2.section-h em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright)}\n.oth-hp .section-sub{font-size:17px;line-height:1.62;color:var(--white-soft);max-width:820px;margin-bottom:48px}\n.oth-hp .section-sub strong{color:var(--white);font-weight:600}\n.oth-hp .section-sub em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp h3{font-family:var(--font-sans);font-size:20px;font-weight:600;line-height:1.3;letter-spacing:-0.01em;color:var(--white);margin-bottom:10px}\n.oth-hp h3 em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright)}\n.oth-hp p{font-size:15.5px;line-height:1.68;color:var(--white-soft);margin-bottom:14px}\n.oth-hp p:last-child{margin-bottom:0}\n.oth-hp p strong{color:var(--white);font-weight:600}\n.oth-hp p em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright);letter-spacing:0}\n.oth-hp .hero{padding:100px 0 88px;background:radial-gradient(ellipse at 70% 30%,rgba(237,64,54,.08) 0%,transparent 55%),var(--black);border-bottom:1px solid var(--black-line);position:relative;overflow:hidden}\n.oth-hp .hero::before{content:\"\";position:absolute;top:0;right:0;width:600px;height:600px;background:radial-gradient(circle,rgba(237,64,54,.06) 0%,transparent 70%);pointer-events:none}\n.oth-hp .hero-grid{display:grid;grid-template-columns:1fr 380px;gap:64px;align-items:start;position:relative;z-index:1}\n.oth-hp .hero-tag{display:inline-flex;align-items:center;gap:10px;padding:7px 14px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:999px;font-family:var(--font-mono);font-size:11px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);margin-bottom:24px}\n.oth-hp .hero-tag-dot{width:6px;height:6px;border-radius:50%;background:var(--red-bright);box-shadow:0 0 8px var(--red-bright)}\n.oth-hp h1.hero-h{font-family:var(--font-sans);font-size:clamp(34px,5.5vw,68px);font-weight:800;line-height:1.04;letter-spacing:-0.03em;color:var(--white);margin-bottom:8px}\n.oth-hp h1.hero-h em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright);letter-spacing:-0.01em}\n.oth-hp .hero-accent-bar{width:88px;height:5px;background:linear-gradient(90deg,var(--red-deep),var(--red-bright));border-radius:3px;margin:22px 0 26px}\n.oth-hp .hero-lead{font-size:18px;line-height:1.62;color:var(--white-soft);max-width:640px;margin-bottom:36px}\n.oth-hp .hero-lead strong{color:var(--white);font-weight:600}\n.oth-hp .hero-lead em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright)}\n.oth-hp .hero-stats{display:grid;grid-template-columns:repeat(4,1fr);gap:18px;margin-bottom:36px;padding:22px;background:var(--black-elev);border:1px solid var(--black-line);border-radius:14px}\n.oth-hp .stat-item{display:flex;flex-direction:column;gap:6px}\n.oth-hp .stat-num{font-family:var(--font-display);font-style:italic;font-weight:600;font-size:32px;line-height:1;color:var(--red-bright);letter-spacing:-0.02em}\n.oth-hp .stat-label{font-family:var(--font-mono);font-size:10px;font-weight:500;letter-spacing:0.1em;text-transform:uppercase;color:var(--white-mute);line-height:1.3}\n.oth-hp .hero-ctas{display:flex;gap:14px;flex-wrap:wrap}\n.oth-hp .btn{display:inline-flex;align-items:center;gap:10px;padding:14px 26px;border-radius:999px;font-family:var(--font-mono);font-size:12px;font-weight:700;letter-spacing:0.1em;text-transform:uppercase;transition:all .25s;cursor:pointer;border:1px solid transparent;text-align:center}\n.oth-hp .btn-primary{background:var(--red);color:var(--white);box-shadow:0 4px 14px rgba(237,64,54,.35)}\n.oth-hp .btn-primary:hover{background:var(--red-bright);transform:translateY(-2px);box-shadow:0 8px 22px rgba(237,64,54,.45)}\n.oth-hp .btn-ghost{background:transparent;color:var(--white);border-color:var(--white-line)}\n.oth-hp .btn-ghost:hover{border-color:var(--red-bright);color:var(--red-bright);background:rgba(237,64,54,.05)}\n.oth-hp .btn svg{width:14px;height:14px;stroke:currentColor;stroke-width:2.2;fill:none}\n.oth-hp .hero-card{background:linear-gradient(135deg,var(--black-elev) 0%,var(--black-card) 100%);border:1px solid var(--black-line);border-radius:18px;padding:28px;position:sticky;top:100px}\n.oth-hp .hero-card-head{display:flex;align-items:center;justify-content:space-between;padding-bottom:18px;border-bottom:1px solid var(--black-line);margin-bottom:20px}\n.oth-hp .hero-card-title{font-family:var(--font-mono);font-size:10.5px;font-weight:600;letter-spacing:0.14em;text-transform:uppercase;color:var(--white-mute)}\n.oth-hp .hero-card-badge{font-family:var(--font-mono);font-size:10px;font-weight:600;padding:4px 9px;background:rgba(237,64,54,.12);color:var(--red-bright);border-radius:999px;border:1px solid rgba(237,64,54,.3);letter-spacing:0.08em}\n.oth-hp .hero-card-subs{display:flex;flex-direction:column;gap:10px;margin-bottom:22px}\n.oth-hp .hero-card-sub{display:block;padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;transition:all .25s}\n.oth-hp .hero-card-sub:hover{border-color:rgba(237,64,54,.4);background:var(--black-card);transform:translateX(3px)}\n.oth-hp .hero-card-sub-k{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:4px;display:flex;align-items:center;gap:6px}\n.oth-hp .hero-card-sub-k::before{content:\"\u2693\";opacity:.8}\n.oth-hp .hero-card-sub-h{font-family:var(--font-sans);font-size:14px;font-weight:600;color:var(--white);line-height:1.3;margin-bottom:3px}\n.oth-hp .hero-card-sub-h em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .hero-card-sub-text{font-size:11.5px;line-height:1.5;color:var(--white-mute)}\n.oth-hp .hero-card-foot{padding-top:18px;border-top:1px solid var(--black-line);font-size:12px;color:var(--white-mute);line-height:1.55}\n.oth-hp .what-grid{display:grid;grid-template-columns:1.2fr 1fr;gap:48px;align-items:start;margin-bottom:48px}\n.oth-hp .what-text p{margin-bottom:16px;font-size:16px;line-height:1.72}\n.oth-hp .what-card{background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:30px;position:relative;overflow:hidden}\n.oth-hp .what-card::before{content:\"\";position:absolute;top:0;left:0;width:4px;height:100%;background:linear-gradient(180deg,var(--red-deep),var(--red-bright))}\n.oth-hp .what-card-eyebrow{font-family:var(--font-mono);font-size:10.5px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);margin-bottom:14px}\n.oth-hp .what-card-h{font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);margin-bottom:14px;line-height:1.35}\n.oth-hp .what-card-list{list-style:none;display:flex;flex-direction:column;gap:12px}\n.oth-hp .what-card-list li{display:flex;gap:12px;font-size:14px;line-height:1.55;color:var(--white-soft)}\n.oth-hp .what-card-list li::before{content:\"\";flex-shrink:0;width:14px;height:14px;margin-top:4px;background:url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 24 24' fill='none' stroke='%23ED4036' stroke-width='2.5' stroke-linecap='round' stroke-linejoin='round'><polyline points='20 6 9 17 4 12'\/><\/svg>\") center\/contain no-repeat}\n.oth-hp .what-card-list li strong{color:var(--white);font-weight:600}\n.oth-hp .cross-hub{padding:30px 32px;background:linear-gradient(135deg,rgba(237,64,54,.06),rgba(237,64,54,0));border:1px solid rgba(237,64,54,.25);border-radius:14px;display:grid;grid-template-columns:repeat(2,1fr);gap:24px}\n.oth-hp .cross-hub-card{display:block;padding:18px 20px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:12px;transition:all .25s}\n.oth-hp .cross-hub-card:hover{border-color:rgba(237,64,54,.4);background:var(--black-card);transform:translateY(-2px)}\n.oth-hp .cross-hub-eyebrow{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);margin-bottom:8px}\n.oth-hp .cross-hub-h{font-family:var(--font-sans);font-size:15px;font-weight:600;color:var(--white);line-height:1.35;margin-bottom:6px;letter-spacing:-0.01em}\n.oth-hp .cross-hub-h em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .cross-hub-text{font-size:12px;line-height:1.55;color:var(--white-mute)}\n.oth-hp .cross-hub-text strong{color:var(--white-soft);font-weight:600}\n<\/style>\n\n<div class=\"read-progress\" id=\"oth-hp-progress\" aria-hidden=\"true\"><\/div>\n\n<nav class=\"sticky-nav\" id=\"oth-hp-stickynav\" aria-label=\"Section navigation\">\n  <span class=\"sticky-nav-label\">On this page<\/span>\n  <div class=\"sticky-nav-links\">\n    <a href=\"#what\" data-target=\"what\">What<\/a>\n    <a href=\"#regulatory\" data-target=\"regulatory\">Regulatory<\/a>\n    <a href=\"#hospitals\" data-target=\"hospitals\">Hospitals<\/a>\n    <a href=\"#pharma\" data-target=\"pharma\">Pharma<\/a>\n    <a href=\"#medical-devices\" data-target=\"medical-devices\">Med Devices<\/a>\n    <a href=\"#clinical\" data-target=\"clinical\">Clinical<\/a>\n    <a href=\"#frameworks\" data-target=\"frameworks\">Frameworks<\/a>\n    <a href=\"#engagement\" data-target=\"engagement\">Engagement<\/a>\n    <a href=\"#faq\" data-target=\"faq\">FAQ<\/a>\n  <\/div>\n  <a href=\"#engage\" class=\"sticky-nav-cta\">Engage<\/a>\n<\/nav>\n\n<a href=\"#engage\" class=\"float-cta\" id=\"oth-hp-floatcta\">Engage \u2192<\/a>\n\n<div class=\"status-strip\">\n  <div class=\"status-inner\">\n    <div class=\"status-left\">\n      <span class=\"status-dot\" aria-hidden=\"true\"><\/span>\n      <span>Healthcare &amp; Pharma \u00b7 FDA Thailand \u00b7 MoPH \u00b7 Drug Act B.E. 2510 \u00b7 Medical Device Act B.E. 2551<\/span>\n      <span class=\"status-pill\">Hub 4 of 8<\/span>\n    <\/div>\n    <div class=\"status-left\">\n      <span>Bangkok \u00b7 GMT+7<\/span>\n      <span class=\"status-pill\">In-house bench<\/span>\n    <\/div>\n  <\/div>\n<\/div>\n\n<nav class=\"crumb\" aria-label=\"Breadcrumb\">\n  <div class=\"crumb-inner\">\n    <a href=\"\/\">Home<\/a>\n    <span class=\"crumb-sep\">\u203a<\/span>\n    <a href=\"\/industries\/\">Industries<\/a>\n    <span class=\"crumb-sep\">\u203a<\/span>\n    <span class=\"crumb-current\">Healthcare &amp; Pharma<\/span>\n  <\/div>\n<\/nav>\n\n<section class=\"hero\" id=\"hero\">\n  <div class=\"container\">\n    <div class=\"hero-grid\">\n      <div>\n        <div class=\"hero-tag\">\n          <span class=\"hero-tag-dot\" aria-hidden=\"true\"><\/span>\n          <span>Healthcare &amp; Pharma \u00b7 FDA Thailand \/ MoPH \/ NHSO anchored<\/span>\n        <\/div>\n        <h1 class=\"hero-h\">Healthcare &amp; Pharma \u2014<br><em>the regulated tier.<\/em><\/h1>\n        <div class=\"hero-accent-bar\" aria-hidden=\"true\"><\/div>\n        <p class=\"hero-lead\">\n          Thai healthcare &amp; pharma sits on <strong>a layered regulatory architecture few generalist vendors operate to operationally<\/strong> \u2014 the Thai Food and Drug Administration (FDA Thailand) under the Ministry of Public Health (MoPH) administering the Drug Act B.E. 2510 (1967, as amended) for pharmaceuticals and the Medical Device Act B.E. 2551 (2008) for medical devices; the Health Facility Act B.E. 2541 (1998) governing hospitals and clinics; the three-scheme universal coverage framework (NHSO-administered Universal Coverage Scheme, SSO Social Security Scheme, Comptroller General-administered CSMBS) covering ~99% of the Thai population; PIC\/S-acceded GMP for pharmaceutical manufacturing (Thailand acceded 2016); ICH-GCP for clinical research; and the 2019 PDPA B.E. 2562 for clinical-data and patient-record handling. <em>Plus the EEC &#8220;medical hub and total healthcare services&#8221; targeted-industry positioning and a substantial SET-listed hospital group universe led by BDMS, BH, BCH, CHG, THG<\/em>. Verifiable through FDA Thailand, MoPH, NHSO, and Medical Council publications.\n        <\/p>\n\n        <div class=\"hero-stats\">\n          <div class=\"stat-item\">\n            <span class=\"stat-num\">4<\/span>\n            <span class=\"stat-label\">Sub-sectors<br>covered<\/span>\n          <\/div>\n          <div class=\"stat-item\">\n            <span class=\"stat-num\">~99%<\/span>\n            <span class=\"stat-label\">Population covered<br>3-scheme framework<\/span>\n          <\/div>\n          <div class=\"stat-item\">\n            <span class=\"stat-num\">2016<\/span>\n            <span class=\"stat-label\">PIC\/S accession<br>Thailand GMP<\/span>\n          <\/div>\n          <div class=\"stat-item\">\n            <span class=\"stat-num\">2026<\/span>\n            <span class=\"stat-label\">FTSE Russell + IFRS S2<br>inflection point<\/span>\n          <\/div>\n        <\/div>\n\n        <div class=\"hero-ctas\">\n          <a href=\"#engage\" class=\"btn btn-primary\">\n            <span>Scope a Healthcare &amp; Pharma Engagement<\/span>\n            <svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M5 12h14M13 6l6 6-6 6\"\/><\/svg>\n          <\/a>\n          <a href=\"#regulatory\" class=\"btn btn-ghost\">\n            <svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><polyline points=\"22 12 18 12 15 21 9 3 6 12 2 12\"\/><\/svg>\n            <span>FDA + MoPH + NHSO architecture<\/span>\n          <\/a>\n        <\/div>\n      <\/div>\n\n      <aside class=\"hero-card\" aria-label=\"Sub-sectors covered\">\n        <div class=\"hero-card-head\">\n          <span class=\"hero-card-title\">4 sub-sectors covered<\/span>\n          <span class=\"hero-card-badge\">\u2693 Anchored<\/span>\n        <\/div>\n        <div class=\"hero-card-subs\">\n          <a href=\"#hospitals\" class=\"hero-card-sub\">\n            <div class=\"hero-card-sub-k\">Sub-sector 01<\/div>\n            <div class=\"hero-card-sub-h\"><em>Hospital Groups<\/em><\/div>\n            <div class=\"hero-card-sub-text\">BDMS \u00b7 BH \u00b7 BCH \u00b7 CHG \u00b7 RAM \u00b7 THG \u00b7 VIBHA \u00b7 PR9 \u00b7 medical tourism hub \u00b7 JCI accreditation \u00b7 Health Facility Act B.E. 2541<\/div>\n          <\/a>\n          <a href=\"#pharma\" class=\"hero-card-sub\">\n            <div class=\"hero-card-sub-k\">Sub-sector 02<\/div>\n            <div class=\"hero-card-sub-h\"><em>Pharma<\/em><\/div>\n            <div class=\"hero-card-sub-text\">GPO state \u00b7 Mega Lifesciences \u00b7 Thaipharm \u00b7 international JVs (Pfizer\/GSK\/AZ\/Roche\/Novartis) \u00b7 Drug Act B.E. 2510 \u00b7 PIC\/S GMP<\/div>\n          <\/a>\n          <a href=\"#medical-devices\" class=\"hero-card-sub\">\n            <div class=\"hero-card-sub-k\">Sub-sector 03<\/div>\n            <div class=\"hero-card-sub-h\"><em>Medical Devices<\/em><\/div>\n            <div class=\"hero-card-sub-text\">Medical Device Act B.E. 2551 \u00b7 risk-class registration \u00b7 ISO 13485 QMS \u00b7 EEC medical hub manufacturing \u00b7 device import \/ domestic<\/div>\n          <\/a>\n          <a href=\"#clinical\" class=\"hero-card-sub\">\n            <div class=\"hero-card-sub-k\">Sub-sector 04<\/div>\n            <div class=\"hero-card-sub-h\"><em>Clinical Research<\/em><\/div>\n            <div class=\"hero-card-sub-text\">Regional CRO hub \u00b7 ICH-GCP \u00b7 Ethics Committee approval \u00b7 FDA Thailand IND\/CTA \u00b7 PDPA B.E. 2562 \u00b7 biotech promotion BOI A1+<\/div>\n          <\/a>\n        <\/div>\n        <div class=\"hero-card-foot\">\n          <strong>Parent SET classification:<\/strong> SERVICE industry group \u00b7 Health Care Services sector for hospital groups. Pharma + medical devices vary in SET classification depending on the issuer&#8217;s principal operations. <em>EEC &#8220;medical hub and total healthcare services&#8221; is one of the 12 EEC targeted industries<\/em>.\n        <\/div>\n      <\/aside>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"what\">\n  <div class=\"container\">\n    <div class=\"eyebrow\">Section 01 \u00b7 What healthcare &amp; pharma work means<\/div>\n    <h2 class=\"section-h\">Thai healthcare is a <em>multi-regulator discipline.<\/em><\/h2>\n    <p class=\"section-sub\">For institutional procurement in Thai healthcare &amp; pharma, &#8220;industry coverage&#8221; splits into <strong>four operational requirements<\/strong> \u2014 fluency in the FDA Thailand product-registration architecture (drugs under Drug Act B.E. 2510, medical devices under Medical Device Act B.E. 2551, food under Food Act B.E. 2522, cosmetics under Cosmetic Act B.E. 2558); mastery of the Ministry of Public Health hospital framework under the Health Facility Act B.E. 2541 (1998) plus Medical Council of Thailand physician licensing; substantive awareness of the three-scheme universal coverage architecture (NHSO Universal Coverage Scheme since 2002 \/ SSO Social Security Scheme \/ CSMBS for civil servants \u2014 covering ~99% of the Thai population); and operational alignment with the international standards stack (PIC\/S GMP for pharmaceutical manufacturing since Thailand&#8217;s 2016 accession, ICH-GCP for clinical research, ISO 13485 for medical device quality management systems, JCI accreditation for international-tier hospitals, PDPA B.E. 2562 for clinical data and patient records). <em>Generalist healthcare-vertical vendors who treat &#8220;healthcare&#8221; as a single category do not produce institutional-tier output<\/em>; the regulator-specificity and standards layering is what separates procurement-grade from marketing claim.<\/p>\n\n    <div class=\"what-grid\">\n      <div class=\"what-text\">\n        <p>The substantive claim of &#8220;healthcare &amp; pharma coverage&#8221; splits into four operational requirements. <strong>First<\/strong>, FDA Thailand product-registration architecture. <em>The Thai Food and Drug Administration (FDA Thailand) sits under the Ministry of Public Health (MoPH)<\/em> and administers five core registration regimes through dedicated divisions: <strong>Drug Control Division<\/strong> (Drug Act B.E. 2510 of 1967 as amended through 2019); <strong>Medical Device Control Division<\/strong> (Medical Device Act B.E. 2551 of 2008, which replaced the 1971 Act and introduced risk-based class I-IV registration); <strong>Food Division<\/strong> (Food Act B.E. 2522 of 1979); <strong>Cosmetic Division<\/strong> (Cosmetic Act B.E. 2558 of 2015); plus <strong>Narcotics &amp; Psychotropic Substances Division<\/strong>. The Drug Act amendments expanded the modern regulatory categories (originator vs generic, conditional approval pathways, controlled distribution); the Medical Device Act B.E. 2551 brought Thailand toward international risk-classification harmonization. Vendors who treat these registration regimes interchangeably or misallocate jurisdictional authority produce documents that read as substantively wrong to anyone in Thai healthcare procurement.<\/p>\n        <p><strong>Second<\/strong>, hospital and physician framework mastery. <em>The Health Facility Act B.E. 2541 (1998)<\/em> governs the licensing and operation of hospitals (private and public), clinics, polyclinics, and specialty centers under MoPH oversight \u2014 license categories track facility size, scope of services, and specialty designation. <em>The Medical Council of Thailand (Medical Professions Act B.E. 2525 of 1982)<\/em> administers physician licensing, specialty certification, and disciplinary matters; the <em>Pharmacy Council of Thailand<\/em> administers pharmacist licensing; the <em>Nursing Council of Thailand<\/em> administers nursing professional regulation. <strong>Joint Commission International (JCI) accreditation<\/strong> is the international-tier hospital quality standard adopted by every major Thai medical-tourism hospital \u2014 Bangkok Hospital (BDMS network), Bumrungrad International, Samitivej, BNH, Phyathai, Praram 9, Vibhavadi \u2014 and provides the procurement-grade signal for international patients and corporate accounts.<\/p>\n        <p><strong>Third<\/strong>, three-scheme universal coverage architecture. Thailand achieved near-universal health coverage through three parallel schemes that together cover approximately 99% of the population. <em>Universal Coverage Scheme (UCS)<\/em>, administered by the National Health Security Office (NHSO) since 2002 under the National Health Security Act B.E. 2545 \u2014 the largest scheme, covering all Thai citizens not otherwise enrolled, originally called the &#8220;30-baht scheme&#8221; (now zero-baht point-of-service for most). <em>Social Security Scheme (SSS)<\/em>, administered by the Social Security Office (SSO) under the Social Security Act B.E. 2533 \u2014 covers formal-sector private employees with tripartite financing (employer, employee, government). <em>Civil Servant Medical Benefit Scheme (CSMBS)<\/em>, administered by the Comptroller General&#8217;s Department of the Ministry of Finance \u2014 covers civil servants and dependents. <strong>The three schemes have different reimbursement methodologies, drug formularies, and provider-network structures<\/strong> \u2014 substantive awareness affects every translation involving Thai hospital billing, drug pricing, hospital procurement, or pharmaceutical access. The <em>National List of Essential Medicines (NLEM)<\/em> \u2014 administered by HITAP (Health Intervention and Technology Assessment Program) under the National Health Security Board \u2014 is the central drug-formulary mechanism.<\/p>\n        <p><strong>Fourth<\/strong>, international standards layering. <em>Thailand acceded to the Pharmaceutical Inspection Co-operation Scheme (PIC\/S) in 2016<\/em>, aligning Thai pharmaceutical GMP with the international PIC\/S guide \u2014 operationally substantive for pharmaceutical manufacturing facility inspection, export documentation, and dossier preparation. <em>ICH-GCP (International Council for Harmonisation Good Clinical Practice)<\/em> is the operational standard for clinical research and clinical trial conduct in Thailand. <em>ISO 13485:2016 (Quality Management Systems for Medical Devices)<\/em> applies to manufacturers seeking Medical Device Act registration and export market access. <em>JCI accreditation<\/em> for hospitals. <em>PDPA B.E. 2562 (2019)<\/em> \u2014 Personal Data Protection Act \u2014 applies to all personal data including clinical records and patient identifiers, with specific operational implications for clinical research data sharing and cross-border data flow. <em>EEC &#8220;medical hub and total healthcare services&#8221;<\/em> sits as one of the 12 EEC targeted industries \u2014 BOI promotion accessible for international-tier hospitals, medical-device manufacturing, biotechnology, and clinical research operations. Cross-link to <a href=\"\/esg-advisory\/\" style=\"color:var(--red-bright);border-bottom:1px solid rgba(237,64,54,.4)\">\/esg-advisory\/<\/a> for the 2026 inflection-point treatment (FTSE Russell ESG, IFRS S2, draft Climate Change Act) as it applies to SET-listed healthcare issuers.<\/p>\n      <\/div>\n\n      <aside class=\"what-card\">\n        <div class=\"what-card-eyebrow\">Substantive healthcare claim \u00b7 what it means<\/div>\n        <div class=\"what-card-h\">What separates institutional-tier Thai healthcare coverage from generic healthcare-vertical claims<\/div>\n        <ul class=\"what-card-list\">\n          <li><strong>FDA Thailand fluency<\/strong> \u2014 Drug Act B.E. 2510 \u00b7 Medical Device Act B.E. 2551 \u00b7 Food Act B.E. 2522 \u00b7 Cosmetic Act B.E. 2558 \u00b7 narcotic \/ psychotropic substances<\/li>\n          <li><strong>Hospital framework<\/strong> \u2014 Health Facility Act B.E. 2541 \u00b7 MoPH oversight \u00b7 Medical Council + Pharmacy Council + Nursing Council \u00b7 JCI international-tier<\/li>\n          <li><strong>Three-scheme coverage<\/strong> \u2014 UCS (NHSO since 2002) \u00b7 SSS (SSO) \u00b7 CSMBS (Comptroller General) \u00b7 NLEM formulary \u00b7 HITAP HTA \u00b7 ~99% population<\/li>\n          <li><strong>PIC\/S GMP since 2016<\/strong> \u2014 pharmaceutical manufacturing \u00b7 facility inspection \u00b7 export dossier \u00b7 originator + generic + biosimilar pathways<\/li>\n          <li><strong>ICH-GCP<\/strong> \u2014 clinical research \u00b7 trial conduct \u00b7 Ethics Committee \u00b7 IND\/CTA \u00b7 multi-site coordination \u00b7 Thailand regional CRO hub<\/li>\n          <li><strong>ISO 13485 + IMDRF<\/strong> \u2014 medical device QMS \u00b7 risk-class registration I\/II\/III\/IV \u00b7 post-market surveillance \u00b7 EEC medical hub manufacturing<\/li>\n          <li><strong>PDPA B.E. 2562 (2019)<\/strong> \u2014 clinical data \u00b7 patient records \u00b7 cross-border data flow \u00b7 informed consent \u00b7 data controller \/ processor<\/li>\n          <li><strong>EEC medical hub positioning<\/strong> \u2014 1 of 12 targeted industries \u00b7 BOI A1+ for biotech \u00b7 international-tier hospital expansion \u00b7 cross-border investment<\/li>\n        <\/ul>\n      <\/aside>\n    <\/div>\n\n    <div class=\"cross-hub\">\n      <a href=\"\/industries\/\" class=\"cross-hub-card\">\n        <div class=\"cross-hub-eyebrow\">\u2191 Parent \u00b7 Industries hub<\/div>\n        <div class=\"cross-hub-h\">Industries hub \u00b7 <em>8 commercial sub-pages<\/em><\/div>\n        <div class=\"cross-hub-text\">Healthcare &amp; Pharma is <strong>hub 4 of 8 commercial sub-pages<\/strong> \u00b7 SET hospital groups under SERVICE \/ Health Care Services; pharma + medical devices distributed across industry groups depending on issuer. See the Industries hub for cross-industry overview.<\/div>\n      <\/a>\n      <a href=\"\/esg-advisory\/\" class=\"cross-hub-card\">\n        <div class=\"cross-hub-eyebrow\">\u2192 Cross-link \u00b7 ESG Advisory<\/div>\n        <div class=\"cross-hub-h\">ESG hub \u00b7 <em>access + governance themes<\/em><\/div>\n        <div class=\"cross-hub-text\">For <strong>SET-listed healthcare issuer ESG disclosure<\/strong> under FTSE Russell ESG methodology \u2014 including access-to-medicines themes, healthcare workforce, supply chain, climate-related disclosure for hospital groups \u2014 see the ESG Advisory hub.<\/div>\n      <\/a>\n    <\/div>\n  <\/div>\n<\/section>\n<style>\n.oth-hp .reg-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:22px;margin-bottom:42px}\n.oth-hp .reg-card{background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:28px;transition:all .3s;display:flex;flex-direction:column;position:relative;overflow:hidden}\n.oth-hp .reg-card::before{content:\"\";position:absolute;top:0;left:0;width:100%;height:3px;background:linear-gradient(90deg,var(--red-deep),var(--red-bright));opacity:0;transition:opacity .25s}\n.oth-hp .reg-card:hover{border-color:rgba(237,64,54,.4);transform:translateY(-3px);box-shadow:0 14px 32px rgba(0,0,0,.42)}\n.oth-hp .reg-card:hover::before{opacity:1}\n.oth-hp .reg-head{display:flex;justify-content:space-between;align-items:flex-start;gap:14px;margin-bottom:14px}\n.oth-hp .reg-code{font-family:var(--font-mono);font-size:11px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;white-space:nowrap}\n.oth-hp .reg-role{font-family:var(--font-mono);font-size:9.5px;color:var(--white-mute);letter-spacing:0.08em;text-align:right;text-transform:uppercase;line-height:1.5}\n.oth-hp .reg-h{font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3;margin-bottom:12px;letter-spacing:-0.01em}\n.oth-hp .reg-h em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .reg-text{font-size:13.5px;line-height:1.68;color:var(--white-soft);margin-bottom:14px;flex-grow:1}\n.oth-hp .reg-text strong{color:var(--white);font-weight:600}\n.oth-hp .reg-text em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .reg-tags{padding-top:14px;border-top:1px solid var(--black-line);display:flex;flex-wrap:wrap;gap:6px}\n.oth-hp .reg-tag{font-family:var(--font-mono);font-size:9.5px;font-weight:500;letter-spacing:0.08em;text-transform:uppercase;color:var(--white-mute);padding:4px 9px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:999px}\n\n.oth-hp .tiers{display:grid;grid-template-columns:repeat(3,1fr);gap:18px;margin-bottom:36px}\n.oth-hp .tier-card{background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:14px;padding:26px;display:flex;flex-direction:column;gap:12px;transition:all .25s}\n.oth-hp .tier-card:hover{border-color:rgba(237,64,54,.4);transform:translateY(-2px)}\n.oth-hp .tier-code{font-family:var(--font-display);font-style:italic;font-weight:700;font-size:32px;color:var(--red-bright);line-height:1;letter-spacing:-0.02em}\n.oth-hp .tier-name{font-family:var(--font-mono);font-size:10.5px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--white-mute);line-height:1.4}\n.oth-hp .tier-cap{font-family:var(--font-sans);font-size:14px;font-weight:600;color:var(--white);padding:10px 12px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:8px;text-align:center}\n.oth-hp .tier-cap em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .tier-text{font-size:12.5px;line-height:1.6;color:var(--white-soft)}\n.oth-hp .tier-text strong{color:var(--white);font-weight:600}\n\n.oth-hp .sub{position:relative;scroll-margin-top:80px}\n.oth-hp .sub-header{display:grid;grid-template-columns:auto 1fr auto;align-items:center;gap:18px;margin-bottom:28px;padding-bottom:18px;border-bottom:2px solid var(--red-deep)}\n.oth-hp .sub-anchor{width:48px;height:48px;border-radius:12px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);display:flex;align-items:center;justify-content:center;font-size:20px;color:var(--red-bright);font-family:var(--font-display);font-style:italic;font-weight:600}\n.oth-hp .sub-eyebrow{font-family:var(--font-mono);font-size:11px;font-weight:600;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);margin-bottom:4px}\n.oth-hp .sub-h{font-family:var(--font-sans);font-size:clamp(24px,3.2vw,34px);font-weight:700;color:var(--white);line-height:1.2;letter-spacing:-0.02em}\n.oth-hp .sub-h em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright)}\n.oth-hp .sub-meta{font-family:var(--font-mono);font-size:10px;letter-spacing:0.08em;color:var(--white-mute);text-align:right;line-height:1.5;text-transform:uppercase}\n.oth-hp .sub-lead{font-size:16px;line-height:1.7;color:var(--white-soft);margin-bottom:32px;max-width:900px}\n.oth-hp .sub-lead strong{color:var(--white);font-weight:600}\n.oth-hp .sub-lead em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .sub-body{display:grid;grid-template-columns:1.4fr 1fr;gap:36px;align-items:start;margin-bottom:32px}\n.oth-hp .sub-text p{margin-bottom:14px;font-size:14.5px;line-height:1.72;color:var(--white-soft)}\n.oth-hp .sub-text p strong{color:var(--white);font-weight:600}\n.oth-hp .sub-text p em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .sub-card{background:var(--black-elev);border:1px solid var(--black-line);border-radius:14px;padding:24px;position:relative;overflow:hidden}\n.oth-hp .sub-card::before{content:\"\";position:absolute;top:0;left:0;width:3px;height:100%;background:linear-gradient(180deg,var(--red-deep),var(--red-bright))}\n.oth-hp .sub-card-eyebrow{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);margin-bottom:12px}\n.oth-hp .sub-card-h{font-family:var(--font-sans);font-size:15px;font-weight:600;color:var(--white);margin-bottom:12px;line-height:1.35}\n.oth-hp .sub-card-list{list-style:none;display:flex;flex-direction:column;gap:9px}\n.oth-hp .sub-card-list li{display:flex;gap:10px;font-size:12.5px;line-height:1.55;color:var(--white-soft)}\n.oth-hp .sub-card-list li::before{content:\"\u203a\";color:var(--red-bright);font-weight:700;flex-shrink:0}\n.oth-hp .sub-card-list li strong{color:var(--white);font-weight:600}\n.oth-hp .sub-card-list li em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .sub-anchors-row{padding:18px 22px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:12px;display:grid;grid-template-columns:auto 1fr;gap:18px;align-items:center;margin-bottom:32px}\n.oth-hp .sub-anchors-k{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);white-space:nowrap}\n.oth-hp .sub-anchors-list{display:flex;flex-wrap:wrap;gap:6px}\n.oth-hp .sub-anchors-tag{font-family:var(--font-mono);font-size:10px;font-weight:500;letter-spacing:0.08em;color:var(--white-soft);padding:5px 10px;background:var(--black-card);border:1px solid var(--black-line);border-radius:999px}\n.oth-hp .sub-anchors-tag em{font-family:var(--font-display);font-style:italic;color:var(--red-bright)}\n.oth-hp .sub-mix{padding:22px 24px;background:linear-gradient(135deg,rgba(237,64,54,.05),rgba(237,64,54,0));border:1px solid rgba(237,64,54,.2);border-radius:12px}\n.oth-hp .sub-mix-eyebrow{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);margin-bottom:12px}\n.oth-hp .sub-mix-h{font-family:var(--font-sans);font-size:16px;font-weight:600;color:var(--white);margin-bottom:14px;line-height:1.35}\n.oth-hp .sub-mix-h em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .sub-mix-cols{display:grid;grid-template-columns:repeat(3,1fr);gap:14px}\n.oth-hp .sub-mix-col{padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px}\n.oth-hp .sub-mix-col-h{font-family:var(--font-mono);font-size:10px;font-weight:700;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:8px}\n.oth-hp .sub-mix-col-text{font-size:11.5px;line-height:1.55;color:var(--white-soft)}\n.oth-hp .sub-mix-col-text strong{color:var(--white);font-weight:600}\n<\/style>\n\n<section id=\"regulatory\">\n  <div class=\"container\">\n    <div class=\"eyebrow\">Section 02 \u00b7 Thai healthcare regulatory architecture<\/div>\n    <h2 class=\"section-h\">FDA Thailand. MoPH. <em>NHSO \/ SSO \/ CSMBS.<\/em><\/h2>\n    <p class=\"section-sub\">The substantive moat of Thai healthcare &amp; pharma work is operational fluency in <strong>the layered regulatory architecture<\/strong> \u2014 FDA Thailand under the Ministry of Public Health for product registration; MoPH supervision of hospitals and clinics under the Health Facility Act B.E. 2541; the three-scheme universal coverage framework (NHSO \/ SSO \/ CSMBS) covering ~99% of the population; the professional councils (Medical Council, Pharmacy Council, Nursing Council); and the international standards layer (PIC\/S GMP since 2016, ICH-GCP, ISO 13485, JCI accreditation, PDPA B.E. 2562). <em>This is the regulatory substance every SET-listed Thai hospital group&#8217;s procurement panel and every pharmaceutical company&#8217;s regulatory affairs team operates against<\/em>.<\/p>\n\n    <div class=\"reg-grid\">\n      <article class=\"reg-card\">\n        <div class=\"reg-head\">\n          <span class=\"reg-code\">FDA Thailand<\/span>\n          <span class=\"reg-role\">Product<br>Registration<br>Authority<\/span>\n        <\/div>\n        <h3 class=\"reg-h\">Thai Food and Drug Administration \u2014 <em>product registration<\/em><\/h3>\n        <p class=\"reg-text\"><strong>The product-registration authority<\/strong> under the Ministry of Public Health. Administers five core registration regimes through dedicated divisions: <em>Drug Control Division<\/em> under the Drug Act B.E. 2510 (1967, as amended through 2019) covering pharmaceuticals (originator, generic, biosimilar, traditional medicine, herbal); <em>Medical Device Control Division<\/em> under the Medical Device Act B.E. 2551 (2008) covering risk-class I-IV registration; <em>Food Division<\/em> under the Food Act B.E. 2522; <em>Cosmetic Division<\/em> under the Cosmetic Act B.E. 2558; <em>Narcotics &amp; Psychotropic Substances Division<\/em>. Dossier requirements, registration timelines, post-market surveillance obligations all flow from FDA Thailand notifications. WHO-pre-qualified for several vaccine and drug categories.<\/p>\n        <div class=\"reg-tags\">\n          <span class=\"reg-tag\">Drug Act B.E. 2510<\/span>\n          <span class=\"reg-tag\">Medical Device Act B.E. 2551<\/span>\n          <span class=\"reg-tag\">Risk-class I-IV<\/span>\n          <span class=\"reg-tag\">WHO pre-qualification<\/span>\n        <\/div>\n      <\/article>\n\n      <article class=\"reg-card\">\n        <div class=\"reg-head\">\n          <span class=\"reg-code\">MoPH<\/span>\n          <span class=\"reg-role\">Hospital<br>Supervision<br>+ Policy<\/span>\n        <\/div>\n        <h3 class=\"reg-h\">Ministry of Public Health \u2014 <em>hospital + policy<\/em><\/h3>\n        <p class=\"reg-text\"><strong>The policy direction body and hospital-supervision authority<\/strong>. Supervises public hospitals (regional, provincial, district, community) through the Office of the Permanent Secretary and dedicated departments; supervises private hospitals under the <em>Health Facility Act B.E. 2541 (1998)<\/em> \u2014 license categories track facility size, scope of services, specialty designation. The Department of Health Service Support (HSS) handles the private hospital licensing function. MoPH operates several specialized departments including the Department of Medical Services, Department of Disease Control (DDC, the COVID response anchor), Department of Health, Department of Mental Health, Department of Medical Sciences (DMSc, the regulatory laboratory). <em>The Permanent Secretary of Public Health chairs the National Health Security Board overseeing the NHSO Universal Coverage Scheme<\/em>.<\/p>\n        <div class=\"reg-tags\">\n          <span class=\"reg-tag\">Health Facility Act B.E. 2541<\/span>\n          <span class=\"reg-tag\">HSS licensing<\/span>\n          <span class=\"reg-tag\">DDC \u00b7 DMSc<\/span>\n          <span class=\"reg-tag\">Hospital tier policy<\/span>\n        <\/div>\n      <\/article>\n\n      <article class=\"reg-card\">\n        <div class=\"reg-head\">\n          <span class=\"reg-code\">NHSO<\/span>\n          <span class=\"reg-role\">Universal<br>Coverage<br>Administrator<\/span>\n        <\/div>\n        <h3 class=\"reg-h\">National Health Security Office \u2014 <em>Universal Coverage Scheme<\/em><\/h3>\n        <p class=\"reg-text\"><strong>Administrator of the Universal Coverage Scheme (UCS)<\/strong> under the National Health Security Act B.E. 2545 (2002). Covers all Thai citizens not enrolled in SSS or CSMBS \u2014 the largest of the three schemes, originally called the &#8220;30-baht scheme&#8221; and now zero-baht point-of-service for most services. <em>The NHSO purchases healthcare services from contracted providers<\/em> (mostly public, some private) on a capitation-based payment system supplemented by case-based payment for inpatient care. Operates the National List of Essential Medicines (NLEM) which determines drug reimbursement; works with HITAP (Health Intervention and Technology Assessment Program) for health technology assessment of new interventions. The NHSO&#8217;s purchasing power makes it operationally central to pharmaceutical pricing in Thailand.<\/p>\n        <div class=\"reg-tags\">\n          <span class=\"reg-tag\">National Health Security Act B.E. 2545<\/span>\n          <span class=\"reg-tag\">UCS \u00b7 ~70% population<\/span>\n          <span class=\"reg-tag\">NLEM formulary<\/span>\n          <span class=\"reg-tag\">HITAP HTA<\/span>\n        <\/div>\n      <\/article>\n\n      <article class=\"reg-card\">\n        <div class=\"reg-head\">\n          <span class=\"reg-code\">SSO \u00b7 CSMBS<\/span>\n          <span class=\"reg-role\">Social Security<br>+ Civil Servant<br>Schemes<\/span>\n        <\/div>\n        <h3 class=\"reg-h\">SSO + CSMBS \u2014 <em>two complementary schemes<\/em><\/h3>\n        <p class=\"reg-text\">Two complementary universal coverage schemes. <strong>Social Security Office (SSO)<\/strong> administers the Social Security Scheme (SSS) under the Social Security Act B.E. 2533 (1990) \u2014 covers formal-sector private employees with tripartite financing (employer + employee + government, typically 5%+5%+2.75% of salary). SSO uses a capitation-based contracted hospital network (members select a hospital at enrolment). <strong>Comptroller General&#8217;s Department<\/strong> under the Ministry of Finance administers the Civil Servant Medical Benefit Scheme (CSMBS) \u2014 covers civil servants, dependents, retirees on a fee-for-service basis at public hospitals. <em>The three schemes have different drug formularies, reimbursement methodologies, and provider-network rules<\/em> \u2014 material for any translation involving Thai hospital billing, pharmaceutical access, or hospital procurement.<\/p>\n        <div class=\"reg-tags\">\n          <span class=\"reg-tag\">Social Security Act B.E. 2533<\/span>\n          <span class=\"reg-tag\">SSS \u00b7 ~20% population<\/span>\n          <span class=\"reg-tag\">CSMBS \u00b7 ~9% population<\/span>\n          <span class=\"reg-tag\">3-scheme ~99% coverage<\/span>\n        <\/div>\n      <\/article>\n    <\/div>\n\n    <h3 style=\"font-family:var(--font-sans);font-size:22px;font-weight:600;color:var(--white);margin-bottom:18px;letter-spacing:-0.015em\">Professional councils \u00b7 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright)\">three licensing bodies<\/em><\/h3>\n    <div class=\"tiers\">\n      <article class=\"tier-card\">\n        <div class=\"tier-code\">MCT<\/div>\n        <div class=\"tier-name\">Medical Council of Thailand<\/div>\n        <div class=\"tier-cap\">Medical Professions Act <em>B.E. 2525<\/em><\/div>\n        <p class=\"tier-text\"><strong>Physician licensing and specialty certification<\/strong>. Administers the medical licensing examination, certifies specialty boards (Royal Colleges across 80+ specialties), maintains disciplinary jurisdiction over Thai physicians. Foreign-trained physicians require MCT examination and licensing. <em>Operationally substantive<\/em> for hospital credentialing, cross-border medical staffing, and physician credential verification.<\/p>\n      <\/article>\n      <article class=\"tier-card\">\n        <div class=\"tier-code\">PCT<\/div>\n        <div class=\"tier-name\">Pharmacy Council of Thailand<\/div>\n        <div class=\"tier-cap\">Pharmacy Profession Act <em>B.E. 2537<\/em><\/div>\n        <p class=\"tier-text\"><strong>Pharmacist licensing and pharmacy practice<\/strong>. Administers pharmacist licensing examination and continuing professional development. Pharmacist-in-charge (PIC) requirement for retail pharmacies and hospital pharmacies. <em>Pharmacy supervises drug dispensing<\/em>; the PCT works closely with FDA Thailand on prescription-only and pharmacy-only drug classification.<\/p>\n      <\/article>\n      <article class=\"tier-card\">\n        <div class=\"tier-code\">NCT<\/div>\n        <div class=\"tier-name\">Nursing Council of Thailand<\/div>\n        <div class=\"tier-cap\">Nursing Profession Act <em>B.E. 2528<\/em><\/div>\n        <p class=\"tier-text\"><strong>Nursing professional regulation<\/strong>. Administers nursing licensing examination, registered nurse (RN) and registered midwife credentials, specialty practice nursing certifications. The NCT supervises nursing education programs and maintains disciplinary jurisdiction. <em>Hospital nursing staffing ratios and credentialing<\/em> all flow from NCT standards.<\/p>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"hospitals\" class=\"sub\">\n  <div class=\"container\">\n    <div class=\"sub-header\">\n      <div class=\"sub-anchor\">01<\/div>\n      <div>\n        <div class=\"sub-eyebrow\">\u2693 Sub-sector 01 \u00b7 Hospital Groups<\/div>\n        <h2 class=\"sub-h\">Hospital groups \u2014 <em>SET-listed, JCI-accredited, medical tourism.<\/em><\/h2>\n      <\/div>\n      <div class=\"sub-meta\">SET SERVICE group<br>Health Care Services<br>JCI accreditation<\/div>\n    <\/div>\n\n    <p class=\"sub-lead\">Thai hospital groups are <strong>a structural feature of the SET<\/strong> \u2014 major hospital operators are SET-listed under the SERVICE industry group \/ Health Care Services sector, with substantive international-tier medical tourism positioning. The anchor groups operate networks of multi-specialty hospitals, often with <em>JCI (Joint Commission International) accreditation<\/em>, English\/Arabic\/Chinese\/Japanese-language services for international patients, and corporate-account contracting with multinational employers. Hospital group AGM materials, 56-1 One Report, investor day RSI, and sustainability reporting all sit at procurement-grade institutional translation tier. <em>The 2026 inflection point applies operationally<\/em> \u2014 FTSE Russell ESG, IFRS S2 climate disclosure, Health Facility Act B.E. 2541 compliance.<\/p>\n\n    <div class=\"sub-body\">\n      <div class=\"sub-text\">\n        <p><strong>The anchor SET-listed hospital groups<\/strong>. <em>Bangkok Dusit Medical Services (BDMS)<\/em> \u2014 Thailand&#8217;s largest private hospital group by market capitalization, operating 50+ hospitals under multiple brand networks: <em>Bangkok Hospital<\/em> (the flagship), <em>Samitivej<\/em> (multi-city premium), <em>BNH Hospital<\/em> (Bangkok), <em>Phyathai<\/em> (Phyathai 1\/2\/3 in Bangkok plus regional locations), <em>Paolo<\/em> (Phyathai-network sister brand), and several regional brands. <em>Bumrungrad International (BH)<\/em> \u2014 internationally renowned medical tourism hospital, the historical anchor for Thailand&#8217;s international medical tourism positioning, JCI-accredited multiple times, multi-language services. <em>Bangkok Chain Hospital (BCH)<\/em> \u2014 operating &#8220;Kasemrad&#8221; hospital network across multiple Thai locations; significant SSS hospital network member. <em>Chularat Hospital Group (CHG)<\/em> \u2014 operating multiple hospitals in Bangkok and surrounding provinces. <em>Ramkhamhaeng Hospital (RAM)<\/em> \u2014 Bangkok hospital, also operates other hospitals. <em>Thonburi Healthcare Group (THG)<\/em> \u2014 Bangkok-anchored hospital group, expanding internationally. <em>Vibhavadi Medical Center (VIBHA)<\/em> \u2014 Bangkok hospital operator. <em>Praram 9 Hospital (PR9)<\/em>, <em>Nonthavej (NTV)<\/em>, <em>Mahachai Hospital<\/em>, <em>BPH<\/em>, <em>Sikarin<\/em>, <em>Lanna Hospital<\/em> \u2014 additional SET-listed hospital operators.<\/p>\n        <p><strong>Medical tourism positioning<\/strong>. Thailand has long been one of Asia&#8217;s leading medical tourism destinations \u2014 Bumrungrad, Bangkok Hospital, Samitivej, BNH, Phyathai, Praram 9, Vejthani all serve substantial international patient flows from the Middle East, North Asia, Australasia, North America, and Europe. The <em>JCI accreditation<\/em> serves as the international-tier quality signal for international patients and corporate accounts. Hospital materials for international patients are typically multilingual: English (primary), Arabic (for Middle Eastern patients), Mandarin\/Cantonese (for North Asian patients), Japanese (for Japanese expatriates and tourists), French\/German (occasional). <em>The EEC &#8220;medical hub and total healthcare services&#8221; positioning is one of the 12 EEC targeted industries<\/em> \u2014 BOI promotion accessible for international-tier hospital expansion in Chachoengsao, Chonburi, Rayong.<\/p>\n        <p><strong>Three-scheme reimbursement substance<\/strong>. The mix of UCS \/ SSS \/ CSMBS payer revenue versus corporate-account \/ international-patient revenue varies sharply across SET-listed hospital groups. <em>BDMS and Bumrungrad<\/em> derive substantial revenue from international patients and corporate accounts. <em>BCH (&#8220;Kasemrad&#8221; network)<\/em> and several regional operators derive significant SSS revenue as contracted SSS hospitals. <em>NHSO contracted hospitals<\/em> tend to be public; private participation in UCS is limited though increasing. <em>Substantive translation implications<\/em>: hospital financial disclosure, segment reporting, and sustainability reporting all reference the payer-mix substance; mistranslating UCS \/ SSS \/ CSMBS distinctions or conflating them with private-pay would read as substantively wrong.<\/p>\n        <p><strong>2026 inflection-point exposure<\/strong>. SET-listed hospital groups face the FTSE Russell ESG Scores transition with healthcare-specific weightings (access to healthcare, healthcare workforce, supply chain ethics, patient safety, data privacy under PDPA carry heavier weight). <em>IFRS S2 climate disclosure<\/em> applies to large hospital operators with substantive Scope 1+2 (energy use), Scope 3 (medical waste, pharmaceutical supply chain, patient travel) emissions. <em>Draft Climate Change Act preparation<\/em> for large hospital networks with substantial energy use. <em>PDPA B.E. 2562 (2019)<\/em> is operationally central \u2014 patient records, clinical data, cross-border patient transfer all sit under PDPA jurisdiction.<\/p>\n      <\/div>\n\n      <aside class=\"sub-card\">\n        <div class=\"sub-card-eyebrow\">What hospital group work pulls operationally<\/div>\n        <div class=\"sub-card-h\">Cross-column engagement profile \u00b7 hospital group annual cycle<\/div>\n        <ul class=\"sub-card-list\">\n          <li><strong>AGM simultaneous<\/strong> \u00b7 investor day RSI \u00b7 semi-annual results \u00b7 56-1 One Report including sustainability section \u00b7 standalone sustainability report<\/li>\n          <li><strong>JCI accreditation cycle<\/strong> \u00b7 accreditation surveyor preparation \u00b7 policy + procedure documentation \u00b7 multilingual signage and patient-facing materials<\/li>\n          <li><strong>International patient services<\/strong> \u00b7 admission paperwork \u00b7 informed consent \u00b7 medical records \u00b7 discharge summaries \u00b7 multilingual (EN\/AR\/ZH\/JA)<\/li>\n          <li><strong>Corporate account contracting<\/strong> \u00b7 MNC employer contracts \u00b7 TPA-network agreements \u00b7 insurance billing<\/li>\n          <li><strong>NHSO \/ SSS \/ CSMBS<\/strong> \u00b7 contracted provider documentation \u00b7 drug procurement under NLEM \u00b7 capitation agreements<\/li>\n          <li><strong>Cross-border M&amp;A<\/strong> \u00b7 regional hospital portfolio acquisition \u00b7 pre-IPO documentation \u00b7 cross-border partner JV<\/li>\n          <li><strong>PDPA B.E. 2562 compliance<\/strong> \u00b7 patient consent \u00b7 clinical data flows \u00b7 data processing agreements<\/li>\n        <\/ul>\n      <\/aside>\n    <\/div>\n\n    <div class=\"sub-anchors-row\">\n      <span class=\"sub-anchors-k\">Anchor SET-listed hospital groups<\/span>\n      <div class=\"sub-anchors-list\">\n        <span class=\"sub-anchors-tag\"><em>BDMS<\/em><\/span>\n        <span class=\"sub-anchors-tag\">Bumrungrad \u00b7 BH<\/span>\n        <span class=\"sub-anchors-tag\">BCH \u00b7 Kasemrad<\/span>\n        <span class=\"sub-anchors-tag\">CHG \u00b7 Chularat<\/span>\n        <span class=\"sub-anchors-tag\">RAM \u00b7 Ramkhamhaeng<\/span>\n        <span class=\"sub-anchors-tag\">THG \u00b7 Thonburi<\/span>\n        <span class=\"sub-anchors-tag\">VIBHA \u00b7 Vibhavadi<\/span>\n        <span class=\"sub-anchors-tag\">PR9 \u00b7 Praram 9<\/span>\n        <span class=\"sub-anchors-tag\">NTV \u00b7 Nonthavej<\/span>\n      <\/div>\n    <\/div>\n\n    <div class=\"sub-mix\">\n      <div class=\"sub-mix-eyebrow\">Capability mix \u00b7 hospital groups<\/div>\n      <h4 class=\"sub-mix-h\">Three columns interlocked for <em>SET-listed hospital group work<\/em><\/h4>\n      <div class=\"sub-mix-cols\">\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Interpretation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>AGM simultaneous<\/strong> \u00b7 investor day RSI \u00b7 board consecutive \u00b7 cross-border M&amp;A \u00b7 JCI surveyor briefings \u00b7 medical board meetings \u00b7 international patient case-conference<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Translation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>56-1 One Report<\/strong> with sustainability section \u00b7 annual sustainability report \u00b7 JCI policy documentation \u00b7 patient consent + records \u00b7 Health Facility Act compliance \u00b7 PDPA documentation<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">ESG Advisory<\/div>\n          <p class=\"sub-mix-col-text\"><strong>FTSE Russell scoring<\/strong> \u00b7 IFRS S2 climate disclosure \u00b7 access-to-healthcare materiality \u00b7 medical waste management \u00b7 supply chain ethics \u00b7 patient data PDPA \u00b7 workforce diversity<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n<section id=\"pharma\" class=\"sub\">\n  <div class=\"container\">\n    <div class=\"sub-header\">\n      <div class=\"sub-anchor\">02<\/div>\n      <div>\n        <div class=\"sub-eyebrow\">\u2693 Sub-sector 02 \u00b7 Pharma<\/div>\n        <h2 class=\"sub-h\">Pharma \u2014 <em>GPO + Mega + international JV layer.<\/em><\/h2>\n      <\/div>\n      <div class=\"sub-meta\">Drug Act B.E. 2510<br>PIC\/S GMP since 2016<br>FDA Thailand Drug Division<\/div>\n    <\/div>\n\n    <p class=\"sub-lead\">Thai pharma operates on a three-tier structure: <strong>the Government Pharmaceutical Organisation (GPO) state-owned manufacturer + bulk purchaser, SET-listed and private domestic manufacturers (Mega Lifesciences, Olic, Thaipharm, Siam Pharmaceutical, BIOTEC vaccine), and Thai subsidiaries \/ distribution partnerships of multinational originators<\/strong> (Pfizer Thailand, GSK, AstraZeneca, Roche, Novartis, Bayer, Sanofi, MSD, Takeda, Boehringer Ingelheim, Astellas, Daiichi Sankyo, Sun Pharma). Registration runs through the FDA Thailand Drug Control Division under the Drug Act B.E. 2510 (1967, as amended). <em>Thailand acceded to PIC\/S in 2016<\/em>, aligning Thai pharmaceutical GMP with the international Pharmaceutical Inspection Co-operation Scheme standard. The NHSO operates the National List of Essential Medicines (NLEM) which determines drug reimbursement under the three-scheme coverage framework; HITAP performs health technology assessment for new drug inclusion. <em>Compulsory licensing of patented pharmaceuticals<\/em> under the Patent Act has been deployed in Thailand for several HIV and cardiovascular medicines historically, with ongoing implications for IP-protected pharmaceutical pricing in Thailand.<\/p>\n\n    <div class=\"sub-body\">\n      <div class=\"sub-text\">\n        <p><strong>Government Pharmaceutical Organisation (GPO)<\/strong>. Established 1966 as a state enterprise under the Ministry of Public Health, GPO operates dual roles as <em>state-owned pharmaceutical manufacturer<\/em> (producing generics, vaccines, antiretrovirals) and <em>bulk procurement coordinator<\/em> for public hospitals under the three coverage schemes. GPO manufactures key generic medications listed in the NLEM and supplies them to NHSO-contracted public hospitals. The bulk procurement function gives GPO substantial pricing leverage. GPO also operates significant antiretroviral generic production for HIV\/AIDS treatment, including products produced under historical compulsory licensing of patented originators. <em>Mega Lifesciences (MEGA)<\/em> \u2014 SET-listed pharmaceutical company with regional distribution + manufacturing across ASEAN and beyond; one of few publicly traded Thai pharma operators with substantial regional footprint. <em>Other domestic operators<\/em> include Olic (Thailand), Siam Pharmaceutical, T Man Pharma, Thai Nakorn Patana (TNP), Berlin Pharmaceutical Industry (BPI), Bangkok Lab &amp; Cosmetic, Pharmaland.<\/p>\n        <p><strong>Multinational originator presence<\/strong>. Thailand hosts substantial Thai subsidiaries and distribution partnerships of major multinational pharmaceutical originators \u2014 Pfizer Thailand, GSK, AstraZeneca, Roche, Novartis, Bayer, Sanofi, MSD (Merck Sharp &amp; Dohme), Takeda, Boehringer Ingelheim, Astellas, Daiichi Sankyo, Sun Pharma, Cipla, Dr. Reddy&#8217;s, Eli Lilly, Bristol Myers Squibb, AbbVie, Servier, Pierre Fabre. <em>Many operate Thai manufacturing operations<\/em> for regional supply \u2014 Bangkok-area, Ayutthaya, and EEC region. Some manufacturing facilities have <em>PIC\/S GMP accreditation<\/em> and export to multiple ASEAN and beyond markets. Distribution typically runs through specialized pharmaceutical distributors (DKSH, Zuellig Pharma) or directly through hospital-channel partnerships.<\/p>\n        <p><strong>Drug Act B.E. 2510 registration substance<\/strong>. The Drug Act B.E. 2510 (1967) \u2014 extensively amended over multiple decades, with substantial 2019 amendments modernizing the registration regime \u2014 establishes the regulatory categories: <em>modern drugs (originator + generic), traditional Thai medicine, herbal medicine<\/em>. Registration requires submission of dossier including CMC (chemistry, manufacturing, controls), pre-clinical and clinical data for new chemical entities, bioequivalence data for generics, stability data, labeling, packaging. FDA Thailand reviews dossiers and issues registration certificates. <em>Post-market surveillance, adverse event reporting, and product recalls<\/em> all flow from FDA Thailand Drug Control Division notifications. Bioequivalence studies for generics are typically conducted at FDA-recognized centers; Thai-conducted BE studies are now broadly accepted regionally. <strong>Compulsory licensing<\/strong> under the Patent Act B.E. 2522 has been deployed in Thailand for HIV antiretrovirals, cardiovascular drugs, and oncology drugs \u2014 landmark deployments occurred 2006-2008, with ongoing IP-policy implications.<\/p>\n        <p><strong>NHSO + HITAP pricing substance<\/strong>. The <em>National List of Essential Medicines (NLEM)<\/em> is the central drug-formulary mechanism. Drugs included on the NLEM are reimbursed under the three-scheme coverage framework; non-NLEM drugs may not be reimbursed depending on scheme rules. <em>HITAP (Health Intervention and Technology Assessment Program)<\/em>, established 2007, conducts health technology assessment (HTA) \u2014 cost-effectiveness analysis, budget impact analysis \u2014 for new drug inclusion in the NLEM. HITAP&#8217;s methodology is internationally respected; HITAP has worked with WHO, World Bank, and counterpart HTA agencies globally. <em>Operationally substantive<\/em> for pharmaceutical company market access strategy in Thailand: dossier preparation for HITAP HTA review, NLEM application documentation, NHSO contract negotiation all sit at procurement-grade translation tier.<\/p>\n      <\/div>\n\n      <aside class=\"sub-card\">\n        <div class=\"sub-card-eyebrow\">What pharma work pulls operationally<\/div>\n        <div class=\"sub-card-h\">Cross-column engagement profile \u00b7 pharmaceutical annual cycle<\/div>\n        <ul class=\"sub-card-list\">\n          <li><strong>FDA Thailand registration<\/strong> \u00b7 drug dossier \u00b7 CMC \u00b7 pre-clinical \/ clinical sections \u00b7 stability data \u00b7 labeling \u00b7 packaging<\/li>\n          <li><strong>HITAP HTA submission<\/strong> \u00b7 cost-effectiveness \u00b7 budget impact \u00b7 NLEM application documentation \u00b7 NHSO contract preparation<\/li>\n          <li><strong>PIC\/S GMP facility<\/strong> \u00b7 facility inspection preparation \u00b7 SOPs \u00b7 validation documentation \u00b7 audit response \u00b7 export dossier<\/li>\n          <li><strong>Bioequivalence studies<\/strong> \u00b7 generic BE study reports \u00b7 clinical study report (CSR) \u00b7 pharmacokinetic data<\/li>\n          <li><strong>Distribution + supply chain<\/strong> \u00b7 DKSH \/ Zuellig Pharma agreements \u00b7 hospital-channel contracts \u00b7 cold chain documentation<\/li>\n          <li><strong>Adverse event reporting<\/strong> \u00b7 post-market surveillance \u00b7 pharmacovigilance \u00b7 MedDRA coding \u00b7 CIOMS reports<\/li>\n          <li><strong>Patent + compulsory licensing<\/strong> \u00b7 IP-protected pharmaceutical positioning \u00b7 access-to-medicines dialogue<\/li>\n          <li><strong>2026 ESG inflection<\/strong> \u00b7 access to medicines \u00b7 supply chain ethics \u00b7 pharmaceutical R&amp;D pipeline disclosure \u00b7 climate Scope 3<\/li>\n        <\/ul>\n      <\/aside>\n    <\/div>\n\n    <div class=\"sub-anchors-row\">\n      <span class=\"sub-anchors-k\">Anchor Thai pharma players<\/span>\n      <div class=\"sub-anchors-list\">\n        <span class=\"sub-anchors-tag\"><em>GPO state<\/em><\/span>\n        <span class=\"sub-anchors-tag\">Mega Lifesciences \u00b7 MEGA<\/span>\n        <span class=\"sub-anchors-tag\">Olic Thailand<\/span>\n        <span class=\"sub-anchors-tag\">Siam Pharm<\/span>\n        <span class=\"sub-anchors-tag\">T Man Pharma<\/span>\n        <span class=\"sub-anchors-tag\">Thai Nakorn Patana<\/span>\n        <span class=\"sub-anchors-tag\">Berlin \u00b7 BPI<\/span>\n        <span class=\"sub-anchors-tag\">DKSH \u00b7 Zuellig Pharma<\/span>\n        <span class=\"sub-anchors-tag\">Pfizer \u00b7 GSK \u00b7 AZ \u00b7 Roche \u00b7 Novartis<\/span>\n      <\/div>\n    <\/div>\n\n    <div class=\"sub-mix\">\n      <div class=\"sub-mix-eyebrow\">Capability mix \u00b7 pharma<\/div>\n      <h4 class=\"sub-mix-h\">Three columns interlocked for <em>pharmaceutical work<\/em><\/h4>\n      <div class=\"sub-mix-cols\">\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Interpretation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>FDA Thailand consultation<\/strong> \u00b7 HITAP HTA hearing \u00b7 medical advisory boards \u00b7 pharmacovigilance \u00b7 PIC\/S facility audits \u00b7 KOL roundtables \u00b7 launch ceremony \u00b7 clinical investigator meetings<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Translation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Drug dossiers<\/strong> \u00b7 clinical study reports \u00b7 CMC documentation \u00b7 labeling + packaging \u00b7 SmPC \/ patient information leaflet \u00b7 stability reports \u00b7 bioequivalence study reports \u00b7 pharmacovigilance<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">ESG Advisory<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Access to medicines<\/strong> framework \u00b7 supply chain ethics \u00b7 pharmaceutical R&amp;D pipeline disclosure \u00b7 climate Scope 3 (manufacturing + distribution + cold chain) \u00b7 GxP compliance disclosure<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"medical-devices\" class=\"sub\">\n  <div class=\"container\">\n    <div class=\"sub-header\">\n      <div class=\"sub-anchor\">03<\/div>\n      <div>\n        <div class=\"sub-eyebrow\">\u2693 Sub-sector 03 \u00b7 Medical Devices<\/div>\n        <h2 class=\"sub-h\">Medical devices \u2014 <em>Medical Device Act B.E. 2551 + EEC hub.<\/em><\/h2>\n      <\/div>\n      <div class=\"sub-meta\">Medical Device Act B.E. 2551<br>ISO 13485 QMS<br>FDA Thailand MD Division<\/div>\n    <\/div>\n\n    <p class=\"sub-lead\">Thai medical devices operate under <strong>the Medical Device Act B.E. 2551 (2008)<\/strong> \u2014 which replaced the original 1971 Act and introduced risk-based class I-IV classification largely aligned with international practice. Registration runs through the FDA Thailand Medical Device Control Division. The substantive market structure includes <em>multinational originator subsidiaries<\/em> (Medtronic, Johnson &amp; Johnson, Boston Scientific, Abbott, Stryker, GE Healthcare, Philips, Siemens Healthineers, Roche Diagnostics, Becton Dickinson, B. Braun, Fresenius, Olympus, Terumo, Nipro, Nihon Kohden), <em>regional and domestic distributors<\/em>, and <em>Thai-domiciled medical device manufacturing operations<\/em> often BOI-promoted under the EEC &#8220;medical hub and total healthcare services&#8221; targeted industry. <em>ISO 13485:2016 (Quality Management Systems for Medical Devices)<\/em> is the operational standard for manufacturers seeking Medical Device Act registration and export market access.<\/p>\n\n    <div class=\"sub-body\">\n      <div class=\"sub-text\">\n        <p><strong>Medical Device Act B.E. 2551 risk-class structure<\/strong>. The Act establishes four risk classes broadly aligned with international IMDRF (International Medical Device Regulators Forum) convention: <em>Class I<\/em> (low risk \u2014 e.g., stethoscope, surgical gauze, examination gloves) with notification-based registration; <em>Class II<\/em> (low-moderate risk \u2014 e.g., hypodermic needle, blood pressure cuff, surgical instruments) with declaration-based registration; <em>Class III<\/em> (moderate-high risk \u2014 e.g., orthopedic implants, infusion pumps, anesthetic machines, ventilators) with full registration including technical file review; <em>Class IV<\/em> (high risk \u2014 e.g., cardiac stents, pacemakers, deep-brain stimulators, joint replacements) with comprehensive registration including clinical data review. <em>The classification determines dossier requirements, review timelines, and post-market surveillance obligations<\/em>. Annexes published by FDA Thailand provide the classification rules and product-specific guidance.<\/p>\n        <p><strong>ISO 13485:2016 QMS as the underlying quality framework<\/strong>. Manufacturers operating medical device facilities in Thailand \u2014 domestic or multinational subsidiary \u2014 typically maintain <em>ISO 13485:2016 certification<\/em> as the operational quality management system standard for medical devices. ISO 13485 covers design and development, risk management (ISO 14971 linkage), production controls, post-market surveillance, complaint handling, CAPA (corrective and preventive action), and management review. ISO 13485 certification provides export market access (EU, US FDA QSR alignment, regional markets). <em>FDA Thailand inspections<\/em> for Class III\/IV manufacturers may reference ISO 13485 compliance as part of the technical file review.<\/p>\n        <p><strong>EEC medical hub positioning + BOI promotion<\/strong>. The EEC &#8220;medical hub and total healthcare services&#8221; is one of the 12 EEC targeted industries under the Eastern Special Development Zone Act B.E. 2561 (2018). <em>BOI promotion for medical device manufacturing<\/em> typically falls into A1+ or A2 categories with up to 8 years CIT exemption (up to 13 years for strategic EEC projects) plus 100% foreign ownership plus machinery and raw materials customs exemption. EEC-located medical device manufacturers benefit from concentration of industrial estate infrastructure, proximity to Laem Chabang port for export, and BOI \/ EEC Office single-window coordination. <em>The growth thesis is regional supply<\/em> \u2014 Thai-manufactured medical devices serving ASEAN and beyond, supported by FTAs and competitive labor costs relative to developed markets.<\/p>\n        <p><strong>Distribution + hospital procurement<\/strong>. Medical device distribution in Thailand operates through <em>specialized medical device distributors and trading houses<\/em> (DKSH, Zuellig Pharma also distribute selected medical devices, plus device-specific distributors), <em>direct hospital sales for capital equipment<\/em> (imaging systems, surgical platforms, hospital information systems), and <em>tender-based public hospital procurement<\/em> under government procurement rules. <em>Public hospital procurement<\/em> follows the Public Procurement and Supplies Administration Act B.E. 2560 (2017) with competitive tender, electronic auction, or selective method procedures. Multinational device companies maintain Thai regulatory affairs and clinical affairs teams to manage Medical Device Act registration, post-market surveillance, and clinical evidence requirements.<\/p>\n      <\/div>\n\n      <aside class=\"sub-card\">\n        <div class=\"sub-card-eyebrow\">What medical device work pulls operationally<\/div>\n        <div class=\"sub-card-h\">Cross-column engagement profile \u00b7 medical device annual cycle<\/div>\n        <ul class=\"sub-card-list\">\n          <li><strong>Medical Device Act registration<\/strong> \u00b7 risk-class I\/II\/III\/IV dossier \u00b7 technical file \u00b7 clinical data (Class III\/IV)<\/li>\n          <li><strong>ISO 13485 QMS<\/strong> \u00b7 audit preparation \u00b7 SOPs \u00b7 design history file \u00b7 risk management file \u00b7 CAPA<\/li>\n          <li><strong>EEC + BOI promotion<\/strong> \u00b7 A1+\/A2 application documentation \u00b7 investment promotion \u00b7 13-year CIT<\/li>\n          <li><strong>Distribution agreements<\/strong> \u00b7 DKSH \/ Zuellig agreements \u00b7 hospital-channel contracts \u00b7 capital equipment quotations<\/li>\n          <li><strong>Public hospital tender<\/strong> \u00b7 Public Procurement Act B.E. 2560 \u00b7 competitive tender \u00b7 technical specifications \u00b7 post-tender evaluation<\/li>\n          <li><strong>Post-market surveillance<\/strong> \u00b7 adverse event reporting \u00b7 field safety corrective action \u00b7 product recall documentation<\/li>\n          <li><strong>2026 ESG inflection<\/strong> \u00b7 supply chain ethics \u00b7 device end-of-life management \u00b7 climate Scope 3 (manufacturing + transport)<\/li>\n        <\/ul>\n      <\/aside>\n    <\/div>\n\n    <div class=\"sub-anchors-row\">\n      <span class=\"sub-anchors-k\">Anchor medical device players<\/span>\n      <div class=\"sub-anchors-list\">\n        <span class=\"sub-anchors-tag\">Medtronic Thailand<\/span>\n        <span class=\"sub-anchors-tag\">J&amp;J \u00b7 Janssen<\/span>\n        <span class=\"sub-anchors-tag\">Abbott \u00b7 BSC<\/span>\n        <span class=\"sub-anchors-tag\">GE Healthcare<\/span>\n        <span class=\"sub-anchors-tag\">Philips \u00b7 Siemens Healthineers<\/span>\n        <span class=\"sub-anchors-tag\">Stryker \u00b7 B.Braun<\/span>\n        <span class=\"sub-anchors-tag\">Olympus \u00b7 Terumo \u00b7 Nipro<\/span>\n        <span class=\"sub-anchors-tag\"><em>EEC medical hub<\/em><\/span>\n      <\/div>\n    <\/div>\n\n    <div class=\"sub-mix\">\n      <div class=\"sub-mix-eyebrow\">Capability mix \u00b7 medical devices<\/div>\n      <h4 class=\"sub-mix-h\">Three columns interlocked for <em>medical device work<\/em><\/h4>\n      <div class=\"sub-mix-cols\">\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Interpretation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>FDA Thailand MD Division<\/strong> \u00b7 BOI \/ EEC Office consultation \u00b7 clinical investigator meetings \u00b7 KOL roundtables \u00b7 trade-show product launches \u00b7 facility audit briefings<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Translation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Medical Device Act dossier<\/strong> \u00b7 technical file \u00b7 ISO 13485 QMS documentation \u00b7 clinical evaluation report \u00b7 IFU (instructions for use) \u00b7 labeling \u00b7 post-market surveillance<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">ESG Advisory<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Supply chain ethics<\/strong> \u00b7 medical device end-of-life \u00b7 climate Scope 3 disclosure \u00b7 conflict minerals 3TG \u00b7 sustainable medical device design \u00b7 BOI A1+ promotion sustainability criteria<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n<section id=\"clinical\" class=\"sub\">\n  <div class=\"container\">\n    <div class=\"sub-header\">\n      <div class=\"sub-anchor\">04<\/div>\n      <div>\n        <div class=\"sub-eyebrow\">\u2693 Sub-sector 04 \u00b7 Clinical Research<\/div>\n        <h2 class=\"sub-h\">Clinical research \u2014 <em>regional CRO hub, ICH-GCP, PDPA.<\/em><\/h2>\n      <\/div>\n      <div class=\"sub-meta\">ICH-GCP standard<br>FDA Thailand IND\/CTA<br>Ethics Committee approval<\/div>\n    <\/div>\n\n    <p class=\"sub-lead\">Thailand is <strong>a regional clinical research hub<\/strong> \u2014 substantial CRO operations (IQVIA Thailand, Parexel, ICON, Syneos, Labcorp Drug Development, PPD, Linical), strong investigator-site networks at university teaching hospitals (Chulalongkorn, Mahidol Siriraj, Mahidol Ramathibodi, Khon Kaen, Chiang Mai), and access to substantive patient populations across infectious disease (HIV\/AIDS, TB, dengue), oncology, cardiovascular, and metabolic disease therapeutic areas. Clinical trial conduct operates under <em>ICH-GCP (International Council for Harmonisation Good Clinical Practice)<\/em> with regulatory oversight by FDA Thailand and ethical oversight by institutional Ethics Committees (ECs \/ IRBs). <em>PDPA B.E. 2562 (2019)<\/em> applies to all clinical research personal data with specific operational implications for informed consent, data processing, and cross-border data transfer.<\/p>\n\n    <div class=\"sub-body\">\n      <div class=\"sub-text\">\n        <p><strong>Regulatory + ethics dual approval<\/strong>. Conducting a clinical trial in Thailand requires <em>two parallel approval streams<\/em>. <strong>Regulatory approval<\/strong>: FDA Thailand Investigational New Drug (IND) submission for drug trials, or Clinical Trial Application (CTA) under the relevant regulatory pathway depending on phase and product class; the Drug Control Division reviews protocol, investigator&#8217;s brochure, manufacturing information, prior clinical experience. <strong>Ethics Committee approval<\/strong>: independent institutional Ethics Committee (typically at the investigator site \u2014 Chulalongkorn IRB, Siriraj IRB, Ramathibodi IRB, KKU EC, CMU EC, Mahidol Central EC, MoPH Central EC) reviews protocol, informed consent form, investigator qualifications, site capacity. <em>Both approvals are required before trial initiation<\/em>; protocol amendments require both regulatory and ethics review. Multi-site trials require Ethics Committee approval at each participating institution.<\/p>\n        <p><strong>ICH-GCP operational substance<\/strong>. Thailand operates clinical research under the <em>ICH E6(R2) Good Clinical Practice<\/em> standard \u2014 the international harmonized standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. ICH-GCP covers investigator responsibilities, sponsor obligations, IRB\/EC functions, trial protocol, investigator&#8217;s brochure, source documents, essential documents, monitoring, audit, inspection, adverse event reporting. <em>FDA Thailand recognises ICH-GCP<\/em> and conducts trial inspections at sites and at CRO operations. Thailand-conducted trial data are widely accepted by US FDA, EMA, PMDA, and Health Canada for regulatory submissions globally \u2014 a substantive feature of Thailand&#8217;s regional CRO positioning. Many Thai investigator sites maintain ICH-GCP certification and participate in international multicenter trials.<\/p>\n        <p><strong>PDPA B.E. 2562 clinical research implications<\/strong>. The Personal Data Protection Act B.E. 2562 (2019) \u2014 operationally effective from June 2022 after several extensions \u2014 applies to all personal data including clinical research data, patient identifiers, genetic data, biometric data. <em>Specific implications for clinical research<\/em>: informed consent must address PDPA-required data subject rights (access, correction, erasure subject to research preservation exemption); data processing agreements (DPAs) required between sponsors, CROs, investigator sites, and laboratory\/imaging providers; cross-border data transfer requires legal-basis assessment (adequacy decision, standard contractual clauses, or specific consent). <em>Many international sponsors<\/em> apply EU GDPR \/ US HIPAA \/ Japan APPI compliance frameworks at the same time as PDPA for multi-region trials \u2014 adding documentation complexity. Translation of informed consent forms (ICFs) into Thai is mandatory; back-translation for sponsor review is standard practice.<\/p>\n        <p><strong>Anchor CRO + site infrastructure<\/strong>. <em>International CROs operating in Thailand<\/em>: IQVIA (largest by global presence with substantial Thai operations), Parexel, ICON, Syneos Health, Labcorp Drug Development (formerly Covance), PPD (now part of Thermo Fisher Scientific), Linical, Worldwide Clinical Trials. <em>Anchor investigator-site institutions<\/em>: <strong>Chulalongkorn University Faculty of Medicine + King Chulalongkorn Memorial Hospital<\/strong> (Bangkok), <strong>Mahidol University Faculty of Medicine Siriraj Hospital<\/strong> (the oldest and largest medical school in Thailand), <strong>Mahidol Ramathibodi Hospital<\/strong> (Bangkok), <strong>Khon Kaen University Faculty of Medicine<\/strong> (Northeast Thailand regional referral center), <strong>Chiang Mai University Faculty of Medicine<\/strong> (Northern Thailand). <em>BOI A1+ promotion is available for biotechnology and clinical research operations<\/em> as part of the EEC medical hub targeted industry.<\/p>\n      <\/div>\n\n      <aside class=\"sub-card\">\n        <div class=\"sub-card-eyebrow\">What clinical research work pulls operationally<\/div>\n        <div class=\"sub-card-h\">Cross-column engagement profile \u00b7 clinical trial conduct<\/div>\n        <ul class=\"sub-card-list\">\n          <li><strong>Protocol + ICF translation<\/strong> \u00b7 protocol synopsis \u00b7 investigator&#8217;s brochure \u00b7 informed consent forms \u00b7 patient-facing materials<\/li>\n          <li><strong>FDA Thailand IND\/CTA<\/strong> \u00b7 drug trial application \u00b7 CMC section \u00b7 investigator qualifications \u00b7 prior clinical experience<\/li>\n          <li><strong>Ethics Committee submission<\/strong> \u00b7 IRB application \u00b7 investigator CV \/ GCP certificates \u00b7 site capacity \u00b7 informed consent<\/li>\n          <li><strong>Investigator meetings<\/strong> \u00b7 simultaneous interpretation \u00b7 multilingual case presentation \u00b7 pharmacovigilance training<\/li>\n          <li><strong>Source data verification<\/strong> \u00b7 CRA monitoring visits \u00b7 audit response \u00b7 regulatory inspection preparation<\/li>\n          <li><strong>Clinical study report (CSR)<\/strong> \u00b7 ICH E3-compliant CSR \u00b7 safety database \u00b7 CIOMS reports \u00b7 MedDRA coding<\/li>\n          <li><strong>PDPA B.E. 2562 compliance<\/strong> \u00b7 DPA between sponsor \/ CRO \/ site \u00b7 informed consent PDPA rights \u00b7 cross-border data transfer<\/li>\n          <li><strong>BOI biotech promotion<\/strong> \u00b7 A1+ application documentation \u00b7 biotechnology clinical research positioning<\/li>\n        <\/ul>\n      <\/aside>\n    <\/div>\n\n    <div class=\"sub-anchors-row\">\n      <span class=\"sub-anchors-k\">Anchor CRO + site infrastructure<\/span>\n      <div class=\"sub-anchors-list\">\n        <span class=\"sub-anchors-tag\">IQVIA \u00b7 Parexel \u00b7 ICON<\/span>\n        <span class=\"sub-anchors-tag\">Syneos \u00b7 Labcorp \u00b7 PPD<\/span>\n        <span class=\"sub-anchors-tag\"><em>Chulalongkorn<\/em><\/span>\n        <span class=\"sub-anchors-tag\">Siriraj \u00b7 Ramathibodi<\/span>\n        <span class=\"sub-anchors-tag\">Khon Kaen U \u00b7 Chiang Mai U<\/span>\n        <span class=\"sub-anchors-tag\">ICH-GCP<\/span>\n        <span class=\"sub-anchors-tag\">PDPA B.E. 2562<\/span>\n      <\/div>\n    <\/div>\n\n    <div class=\"sub-mix\">\n      <div class=\"sub-mix-eyebrow\">Capability mix \u00b7 clinical research<\/div>\n      <h4 class=\"sub-mix-h\">Three columns interlocked for <em>clinical trial work<\/em><\/h4>\n      <div class=\"sub-mix-cols\">\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Interpretation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Investigator meetings<\/strong> \u00b7 simultaneous interpretation \u00b7 CRA monitoring visits \u00b7 regulatory inspection \u00b7 Ethics Committee meetings \u00b7 DSMB (Data Safety Monitoring Board) \u00b7 KOL advisory<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">Translation<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Protocol + amendments<\/strong> \u00b7 investigator&#8217;s brochure \u00b7 informed consent forms (ICFs) \u00b7 patient-facing materials \u00b7 case report form (CRF) \u00b7 clinical study report \u00b7 pharmacovigilance documentation<\/p>\n        <\/div>\n        <div class=\"sub-mix-col\">\n          <div class=\"sub-mix-col-h\">ESG Advisory<\/div>\n          <p class=\"sub-mix-col-text\"><strong>Clinical research ethics<\/strong> \u00b7 informed consent quality \u00b7 data privacy PDPA \u00b7 participant diversity \u00b7 investigator independence \u00b7 publication transparency<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"frameworks\">\n  <div class=\"container\">\n    <div class=\"eyebrow\">Section 07 \u00b7 Standards stack \u00b7 healthcare-specific<\/div>\n    <h2 class=\"section-h\">Standards stack for <em>healthcare &amp; pharma work.<\/em><\/h2>\n    <p class=\"section-sub\">Four standards anchor families operationally active across Thai healthcare &amp; pharma engagement at institutional tier \u2014 Thai healthcare regulatory framework, international quality and GxP standards, ESG framework families relevant to healthcare sectors, and cross-border professional standards. Each family carries its own bilingual termbase and named-entity convention.<\/p>\n\n    <div style=\"display:grid;grid-template-columns:repeat(2,1fr);gap:22px;margin-bottom:36px\">\n      <article style=\"background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Family 01<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">Thai healthcare regulatory \u2014 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">statutory framework<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">The substantive Thai-jurisdiction regulatory framework cluster. <strong style=\"color:var(--white)\">Drug Act B.E. 2510 (1967) as amended<\/strong> for pharmaceuticals; <strong style=\"color:var(--white)\">Medical Device Act B.E. 2551 (2008)<\/strong> for medical devices; <strong style=\"color:var(--white)\">Food Act B.E. 2522 \u00b7 Cosmetic Act B.E. 2558<\/strong>; <strong style=\"color:var(--white)\">Health Facility Act B.E. 2541 (1998)<\/strong>; <strong style=\"color:var(--white)\">Medical Professions \/ Pharmacy \/ Nursing Profession Acts<\/strong>; <strong style=\"color:var(--white)\">National Health Security Act B.E. 2545<\/strong>; <strong style=\"color:var(--white)\">Social Security Act B.E. 2533<\/strong>; <strong style=\"color:var(--white)\">PDPA B.E. 2562<\/strong>.<\/p>\n        <div style=\"padding:14px 16px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:11.5px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Standards stack<\/span>\n          <strong style=\"color:var(--white)\">Drug Act B.E. 2510 \u00b7 Medical Device Act B.E. 2551 \u00b7 Food Act B.E. 2522 \u00b7 Cosmetic Act B.E. 2558 \u00b7 Health Facility Act B.E. 2541 \u00b7 Medical Professions Act B.E. 2525 \u00b7 Pharmacy Profession Act B.E. 2537 \u00b7 Nursing Profession Act B.E. 2528 \u00b7 National Health Security Act B.E. 2545 \u00b7 Social Security Act B.E. 2533 \u00b7 PDPA B.E. 2562<\/strong>\n        <\/div>\n      <\/article>\n\n      <article style=\"background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Family 02<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">GxP + quality \u2014 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">international standards<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">International quality and GxP standards. <strong style=\"color:var(--white)\">PIC\/S GMP<\/strong> (Thailand acceded 2016); <strong style=\"color:var(--white)\">ICH-GCP E6(R2)<\/strong> for clinical research; <strong style=\"color:var(--white)\">ICH-GLP<\/strong> for non-clinical lab; <strong style=\"color:var(--white)\">ISO 13485:2016<\/strong> for medical device QMS; <strong style=\"color:var(--white)\">ISO 14971<\/strong> for risk management; <strong style=\"color:var(--white)\">ISO 15189<\/strong> for medical labs; <strong style=\"color:var(--white)\">JCI accreditation<\/strong>; <strong style=\"color:var(--white)\">IMDRF<\/strong> harmonization; <strong style=\"color:var(--white)\">WHO PQ<\/strong>.<\/p>\n        <div style=\"padding:14px 16px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:11.5px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Standards stack<\/span>\n          <strong style=\"color:var(--white)\">PIC\/S GMP \u00b7 ICH-GCP E6(R2) \u00b7 ICH-GLP \u00b7 ICH-Q \u00b7 ISO 13485:2016 \u00b7 ISO 14971 \u00b7 ISO 15189 \u00b7 JCI \u00b7 IMDRF \u00b7 WHO PQ \u00b7 USP \/ Ph.Eur \/ JP \/ TPC<\/strong>\n        <\/div>\n      <\/article>\n\n      <article style=\"background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Family 03<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">ESG framework \u2014 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">healthcare-sector<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">ESG framework cluster for healthcare. <strong style=\"color:var(--white)\">FTSE Russell ESG<\/strong> with healthcare weightings; <strong style=\"color:var(--white)\">IFRS S1 + S2<\/strong>; <strong style=\"color:var(--white)\">GRI Standards<\/strong> healthcare supplement; <strong style=\"color:var(--white)\">SASB Healthcare<\/strong> (under ISSB); <strong style=\"color:var(--white)\">Access to Medicine Index<\/strong>; <strong style=\"color:var(--white)\">supply chain ethics<\/strong>; <strong style=\"color:var(--white)\">medical waste<\/strong>; <strong style=\"color:var(--white)\">draft Climate Change Act<\/strong>; <strong style=\"color:var(--white)\">PCAF<\/strong> for healthcare financing.<\/p>\n        <div style=\"padding:14px 16px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:11.5px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Standards stack<\/span>\n          <strong style=\"color:var(--white)\">FTSE Russell \u00b7 IFRS S1 + S2 \u00b7 GRI \u00b7 SASB Healthcare \u00b7 ATM Index \u00b7 UNGP healthcare worker rights \u00b7 medical waste \u00b7 draft CCA \u00b7 PCAF<\/strong>\n        <\/div>\n      <\/article>\n\n      <article style=\"background:var(--black-elev);border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Family 04<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">Cross-border professional \u2014 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">international counterparty<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">Professional-services standards. <strong style=\"color:var(--white)\">ISO 17100<\/strong> translation; <strong style=\"color:var(--white)\">ISO 18841 + 20228 + 24019<\/strong> interpretation; <strong style=\"color:var(--white)\">AIIC<\/strong>; <strong style=\"color:var(--white)\">ICH-MedDRA<\/strong> medical dictionary; <strong style=\"color:var(--white)\">SNOMED CT<\/strong>; <strong style=\"color:var(--white)\">ICD-10 \/ ICD-11<\/strong>; <strong style=\"color:var(--white)\">CDISC<\/strong> (CDASH, SDTM, ADaM); <strong style=\"color:var(--white)\">CIOMS<\/strong> pharmacovigilance forms.<\/p>\n        <div style=\"padding:14px 16px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:11.5px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Standards stack<\/span>\n          <strong style=\"color:var(--white)\">ISO 17100 \u00b7 ISO 18841 \u00b7 ISO 20228 \u00b7 ISO 24019 \u00b7 AIIC \u00b7 MedDRA \u00b7 SNOMED CT \u00b7 ICD-10\/11 \u00b7 CDISC \u00b7 CIOMS<\/strong>\n        <\/div>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"engagement\">\n  <div class=\"container\">\n    <div class=\"eyebrow\">Section 08 \u00b7 Healthcare-sector engagement patterns<\/div>\n    <h2 class=\"section-h\">Engagement patterns \u2014 <em>healthcare-sector cycles.<\/em><\/h2>\n    <p class=\"section-sub\">Four substantive engagement patterns in Thai healthcare &amp; pharma, mapped to the operational reality of the sub-sectors and the regulatory cycle.<\/p>\n\n    <div style=\"display:grid;grid-template-columns:repeat(2,1fr);gap:22px\">\n      <article style=\"background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px;position:relative;overflow:hidden\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Pattern 01<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">SET-listed hospital group \u00b7 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">annual integrated cycle<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">A SET SERVICE \/ Health Care Services issuer (BDMS, BH, BCH, CHG, RAM, THG, VIBHA, PR9) running the full annual integrated cycle. <strong style=\"color:var(--white)\">Quarterly board, annual AGM, semi-annual investor day, 56-1 One Report including mandatory sustainability section, standalone sustainability report, FTSE Russell ESG questionnaire response, IFRS S2 phased adoption, JCI accreditation maintenance, PDPA compliance documentation<\/strong>.<\/p>\n        <div style=\"padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:12px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Cycle \u00b7 form \u00b7 capabilities<\/span>\n          <strong style=\"color:var(--white)\">Long-cycle recurring<\/strong> \u00b7 multi-quarter letter \u00b7 3 columns interlocked\n        <\/div>\n      <\/article>\n\n      <article style=\"background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px;position:relative;overflow:hidden\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Pattern 02<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">FDA Thailand registration \u00b7 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">product approval cycle<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">FDA Thailand drug or medical device registration cycle. Drug dossier preparation (CMC, pre-clinical, clinical, labeling), bioequivalence study reports for generics, medical device technical file (Class I\/II\/III\/IV), HITAP HTA submission for NLEM inclusion, post-market surveillance + adverse event reporting. <strong style=\"color:var(--white)\">Project-based engagement<\/strong> with defined product approval timeline.<\/p>\n        <div style=\"padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:12px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Cycle \u00b7 form \u00b7 capabilities<\/span>\n          <strong style=\"color:var(--white)\">Project-based \u00b7 regulated<\/strong> \u00b7 matter letter \u00b7 Translation-heavy\n        <\/div>\n      <\/article>\n\n      <article style=\"background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px;position:relative;overflow:hidden\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Pattern 03<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">Clinical trial conduct \u00b7 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">multi-site programmatic<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">Multi-site clinical trial conduct in Thailand. Protocol + ICF translation, investigator&#8217;s brochure, FDA Thailand IND\/CTA, Ethics Committee submission at each site, investigator meeting interpretation, CRA monitoring, clinical study report (CSR), pharmacovigilance, PDPA-compliant data processing agreements. <strong style=\"color:var(--white)\">Programmatic engagement<\/strong> spanning trial duration.<\/p>\n        <div style=\"padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:12px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Cycle \u00b7 form \u00b7 capabilities<\/span>\n          <strong style=\"color:var(--white)\">Programmatic trial-duration<\/strong> \u00b7 multi-quarter letter \u00b7 Translation + Interpretation \u00b7 ICH-GCP\n        <\/div>\n      <\/article>\n\n      <article style=\"background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:16px;padding:28px;display:flex;flex-direction:column;gap:14px;position:relative;overflow:hidden\">\n        <span style=\"font-family:var(--font-mono);font-size:10.5px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;display:inline-block;align-self:flex-start\">Pattern 04<\/span>\n        <h3 style=\"font-family:var(--font-sans);font-size:18px;font-weight:600;color:var(--white);line-height:1.3\">Cross-border M&amp;A + BOI medical hub \u00b7 <em style=\"font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500\">regional expansion<\/em><\/h3>\n        <p style=\"font-size:13px;line-height:1.65;color:var(--white-soft);flex-grow:1\">Cross-border M&amp;A in healthcare \u2014 hospital portfolio acquisition, pharmaceutical licensing or acquisition, medical device manufacturing JV, BOI A1+ promotion under EEC medical hub targeted industry. <strong style=\"color:var(--white)\">Project-based with regulatory overlay<\/strong>: BOI documentation, EEC Office coordination, FDA Thailand notification, Health Facility Act licensing transfer.<\/p>\n        <div style=\"padding:14px;background:var(--black-soft);border:1px solid var(--black-line);border-radius:10px;font-size:12px;line-height:1.6;color:var(--white-soft)\">\n          <span style=\"font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;color:var(--red-bright);margin-bottom:6px;display:block\">Cycle \u00b7 form \u00b7 capabilities<\/span>\n          <strong style=\"color:var(--white)\">Project-based + privilege<\/strong> \u00b7 counsel-driven letter \u00b7 ESG due diligence\n        <\/div>\n      <\/article>\n    <\/div>\n  <\/div>\n<\/section>\n<style>\n.oth-hp .faq-wrap{max-width:920px;margin:0 auto}\n.oth-hp .faq{background:var(--black-elev);border:1px solid var(--black-line);border-radius:14px;margin-bottom:12px;transition:border-color .2s,box-shadow .2s;overflow:hidden}\n.oth-hp .faq:hover{border-color:var(--red-deep)}\n.oth-hp .faq[open]{border-color:rgba(237,64,54,.35);box-shadow:0 8px 24px rgba(0,0,0,.3)}\n.oth-hp .faq summary{padding:22px 26px;cursor:pointer;list-style:none;display:grid;grid-template-columns:auto 1fr auto;align-items:center;gap:18px;transition:background .15s;font-family:var(--font-sans);font-size:16px;font-weight:600;color:var(--white);line-height:1.4}\n.oth-hp .faq summary::-webkit-details-marker{display:none}\n.oth-hp .faq summary:hover{background:var(--black-card)}\n.oth-hp .faq-num{font-family:var(--font-mono);font-size:11px;font-weight:700;letter-spacing:0.08em;color:var(--red-bright);padding:5px 9px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:6px;white-space:nowrap}\n.oth-hp .faq-icon{width:32px;height:32px;border-radius:50%;background:var(--black-soft);border:1px solid var(--black-line);display:flex;align-items:center;justify-content:center;font-size:18px;font-weight:300;color:var(--red-bright);transition:transform .3s}\n.oth-hp .faq[open] .faq-icon{transform:rotate(45deg);background:var(--red);color:var(--white);border-color:var(--red)}\n.oth-hp .faq-body{padding:0 26px 24px;border-top:1px solid var(--black-line)}\n.oth-hp .faq-body p{font-size:14.5px;line-height:1.72;color:var(--white-soft);margin-top:18px}\n.oth-hp .faq-body p strong{color:var(--white);font-weight:600}\n.oth-hp .faq-body p em{font-family:var(--font-display);font-style:italic;color:var(--red-bright);font-weight:500}\n.oth-hp .engage{padding:96px 0 88px;background:radial-gradient(ellipse at 30% 50%,rgba(237,64,54,.08),transparent 60%),var(--black);border-bottom:1px solid var(--black-line)}\n.oth-hp .engage-grid{display:grid;grid-template-columns:1fr 480px;gap:60px;align-items:start}\n.oth-hp .engage-h{font-family:var(--font-sans);font-size:clamp(30px,4.2vw,52px);font-weight:700;line-height:1.08;letter-spacing:-0.025em;color:var(--white);margin-bottom:22px}\n.oth-hp .engage-h em{font-family:var(--font-display);font-style:italic;font-weight:500;color:var(--red-bright)}\n.oth-hp .engage-lead{font-size:17px;line-height:1.65;color:var(--white-soft);max-width:560px;margin-bottom:32px}\n.oth-hp .engage-lead strong{color:var(--white);font-weight:600}\n.oth-hp .engage-pathways{display:grid;grid-template-columns:repeat(2,1fr);gap:14px;margin-bottom:32px}\n.oth-hp .engage-path{background:var(--black-elev);border:1px solid var(--black-line);border-radius:12px;padding:18px 20px;transition:all .25s;display:block}\n.oth-hp .engage-path:hover{border-color:rgba(237,64,54,.4);background:var(--black-card);transform:translateY(-2px)}\n.oth-hp .engage-path-num{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;color:var(--red-bright);margin-bottom:8px}\n.oth-hp .engage-path-h{font-family:var(--font-sans);font-size:14px;font-weight:600;color:var(--white);line-height:1.35;margin-bottom:6px}\n.oth-hp .engage-path-text{font-size:12.5px;line-height:1.5;color:var(--white-mute)}\n.oth-hp .engage-card{background:linear-gradient(135deg,var(--black-elev),var(--black-card));border:1px solid var(--black-line);border-radius:18px;padding:32px}\n.oth-hp .engage-card-eyebrow{font-family:var(--font-mono);font-size:10.5px;font-weight:600;letter-spacing:0.14em;text-transform:uppercase;color:var(--red-bright);margin-bottom:18px}\n.oth-hp .engage-contact{display:flex;flex-direction:column;gap:16px;margin-bottom:24px}\n.oth-hp .engage-contact-row{display:grid;grid-template-columns:36px 1fr;gap:14px;align-items:start;padding-bottom:16px;border-bottom:1px solid var(--black-line)}\n.oth-hp .engage-contact-row:last-child{border-bottom:none;padding-bottom:0}\n.oth-hp .engage-contact-icon{width:36px;height:36px;border-radius:10px;background:rgba(237,64,54,.1);display:flex;align-items:center;justify-content:center;flex-shrink:0}\n.oth-hp .engage-contact-icon svg{width:17px;height:17px;stroke:var(--red-bright);stroke-width:2;fill:none}\n.oth-hp .engage-contact-k{font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--white-mute);margin-bottom:4px}\n.oth-hp .engage-contact-v{font-size:14.5px;color:var(--white);font-weight:500;line-height:1.5}\n.oth-hp .engage-contact-v a{color:var(--white)}\n.oth-hp .engage-contact-v a:hover{color:var(--red-bright)}\n.oth-hp .engage-cta-row{display:flex;gap:12px;flex-wrap:wrap}\n.oth-hp .oth-footer{background:var(--black-soft);padding:60px 0 40px;border-top:1px solid var(--black-line)}\n.oth-hp .oth-footer-grid{display:grid;grid-template-columns:1.4fr 1fr 1fr 1fr;gap:40px;margin-bottom:42px}\n.oth-hp .oth-footer-brand-h{font-family:var(--font-display);font-style:italic;font-weight:600;font-size:24px;color:var(--white);margin-bottom:14px;letter-spacing:-0.01em}\n.oth-hp .oth-footer-brand-text{font-size:13.5px;line-height:1.65;color:var(--white-mute);margin-bottom:18px}\n.oth-hp .oth-footer-tag{display:inline-flex;align-items:center;gap:8px;font-family:var(--font-mono);font-size:10px;font-weight:600;letter-spacing:0.12em;text-transform:uppercase;color:var(--red-bright);padding:5px 10px;background:rgba(237,64,54,.1);border:1px solid rgba(237,64,54,.3);border-radius:999px}\n.oth-hp .oth-footer-col-h{font-family:var(--font-mono);font-size:10.5px;font-weight:600;letter-spacing:0.14em;text-transform:uppercase;color:var(--white);margin-bottom:18px}\n.oth-hp .oth-footer-links{list-style:none;display:flex;flex-direction:column;gap:10px}\n.oth-hp .oth-footer-links a{font-size:13.5px;color:var(--white-mute);transition:color .2s}\n.oth-hp .oth-footer-links a:hover{color:var(--red-bright)}\n.oth-hp .oth-footer-bottom{padding-top:28px;border-top:1px solid var(--black-line);display:flex;justify-content:space-between;flex-wrap:wrap;gap:14px;font-family:var(--font-mono);font-size:10.5px;letter-spacing:0.08em;color:var(--white-dim);text-transform:uppercase}\n@media (max-width:1100px){.oth-hp .hero-grid,.oth-hp .engage-grid{grid-template-columns:1fr;gap:40px}.oth-hp .hero-card{position:relative;top:auto}.oth-hp .hero-stats{grid-template-columns:repeat(2,1fr)}.oth-hp .what-grid,.oth-hp .sub-body{grid-template-columns:1fr;gap:30px}.oth-hp .reg-grid{grid-template-columns:1fr}.oth-hp .tiers,.oth-hp .sub-mix-cols{grid-template-columns:1fr}.oth-hp .cross-hub{grid-template-columns:1fr}.oth-hp .oth-footer-grid{grid-template-columns:1fr 1fr;gap:32px}.oth-hp .engage-pathways{grid-template-columns:1fr}.oth-hp .sticky-nav-label{display:none}.oth-hp .sub-anchors-row{grid-template-columns:1fr;gap:10px}}\n@media (max-width:768px){.oth-hp section{padding:64px 0}.oth-hp .container{padding:0 20px}.oth-hp h1.hero-h{font-size:clamp(30px,8vw,42px)}.oth-hp h2.section-h{font-size:clamp(26px,6vw,34px)}.oth-hp .sub-h{font-size:clamp(22px,5vw,30px)}.oth-hp .hero{padding:64px 0 56px}.oth-hp .hero-card{padding:22px}.oth-hp .hero-stats{padding:18px;gap:14px}.oth-hp .stat-num{font-size:22px}.oth-hp .hero-ctas{flex-direction:column;align-items:stretch}.oth-hp .hero-ctas .btn{justify-content:center;width:100%}.oth-hp .sub-header{grid-template-columns:auto 1fr;gap:14px}.oth-hp .sub-meta{display:none}.oth-hp .oth-footer-grid{grid-template-columns:1fr;gap:28px}.oth-hp .float-cta{display:inline-flex}.oth-hp .sticky-nav{padding:6px 6px 6px 14px;gap:8px}.oth-hp .sticky-nav-links a{padding:6px 10px;font-size:10px}.oth-hp .sticky-nav-cta{padding:6px 11px;font-size:10px}.oth-hp .faq summary{padding:18px;gap:12px;font-size:14.5px}.oth-hp .faq-body{padding:0 18px 20px}.oth-hp .engage{padding:64px 0 56px}.oth-hp .engage-card{padding:24px}.oth-hp .status-strip{font-size:10px;padding:8px 0}.oth-hp .reg-card{padding:22px}}\n@media (prefers-reduced-motion:reduce){.oth-hp *,.oth-hp *::before,.oth-hp *::after{animation-duration:0.01ms!important;animation-iteration-count:1!important;transition-duration:0.01ms!important;scroll-behavior:auto!important}.oth-hp .status-dot{animation:none}}\n<\/style>\n\n<section id=\"faq\">\n  <div class=\"container\">\n    <div class=\"eyebrow\">Section 09 \u00b7 Healthcare procurement FAQ<\/div>\n    <h2 class=\"section-h\">Procurement-grade <em>questions answered.<\/em><\/h2>\n    <p class=\"section-sub\">Substantive answers to the questions healthcare-sector procurement panels ask when scoping bilingual technical translation, interpretation, and ESG advisory engagement against the FDA Thailand \/ MoPH \/ NHSO \/ SSO \/ CSMBS architecture and 2026 inflection point.<\/p>\n\n    <div class=\"faq-wrap\">\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.01<\/span><span>Why does the FDA Thailand \/ MoPH \/ NHSO separation matter for translation accuracy?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>Because <strong>each institution has distinct statutory authorities and jurisdictional scopes that determine document accuracy<\/strong>. Drug registration is under FDA Thailand Drug Control Division (Drug Act B.E. 2510) \u2014 not &#8220;approved by the Ministry of Public Health&#8221; generically. Hospital licensing is under MoPH Health Facility Act B.E. 2541 administered by HSS \u2014 not &#8220;registered with FDA Thailand.&#8221; Drug reimbursement under Universal Coverage Scheme is determined by NHSO + HITAP HTA process \u2014 not &#8220;set by FDA Thailand.&#8221; Generalist vendors who conflate these institutions produce documents that read as substantively wrong. <em>Multi-institution clarity is one of the substantive markers<\/em> that separates institutional-tier healthcare work from generic vertical-vendor output.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.02<\/span><span>What does the Drug Act B.E. 2510 registration regime look like for pharmaceuticals?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>The <strong>Drug Act B.E. 2510 (1967, as amended through 2019)<\/strong> establishes the regulatory categories: <em>modern drugs (originator, generic, biosimilar), traditional Thai medicine, herbal medicine<\/em>. Registration with FDA Thailand Drug Control Division requires dossier submission including CMC, pre-clinical and clinical data for new chemical entities, bioequivalence data for generics, stability data, labeling. <em>Originator registration may follow streamlined pathways if approved by US FDA, EMA, PMDA, Health Canada<\/em>. Bioequivalence studies for generics conducted at FDA-recognized BE centers. Post-market surveillance + adverse event reporting required throughout product lifecycle. Compulsory licensing under Patent Act B.E. 2522 has historical precedent for HIV antiretrovirals, cardiovascular, oncology drugs.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.03<\/span><span>How does the Medical Device Act B.E. 2551 risk-class system work?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>The <strong>Medical Device Act B.E. 2551 (2008)<\/strong> replaced the 1971 Act and introduced risk-based class I-IV classification broadly aligned with IMDRF practice. <em>Class I<\/em> (low risk \u2014 stethoscopes, gauze, examination gloves) with notification-based registration; <em>Class II<\/em> (low-moderate risk \u2014 needles, BP cuffs) with declaration-based registration; <em>Class III<\/em> (moderate-high risk \u2014 implants, infusion pumps, ventilators) with full registration including technical file review; <em>Class IV<\/em> (high risk \u2014 cardiac stents, pacemakers, joint replacements) with comprehensive registration including clinical data. <em>ISO 13485:2016<\/em> QMS underpins manufacturer quality; <em>ISO 14971<\/em> for risk management.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.04<\/span><span>How do the three coverage schemes UCS \/ SSS \/ CSMBS operationally differ?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>Three parallel schemes covering ~99% of the Thai population. <strong>UCS<\/strong> \u2014 administered by NHSO since 2002 under the National Health Security Act B.E. 2545; ~70% of population; capitation-based payment to contracted providers (mostly public hospitals); uses NLEM formulary. <strong>SSS<\/strong> \u2014 administered by SSO under the Social Security Act B.E. 2533; ~20% of population; tripartite financing (employer + employee + government); members select contracted hospital at enrolment with capitation. <strong>CSMBS<\/strong> \u2014 administered by the Comptroller General&#8217;s Department of the Ministry of Finance; ~9% of population; fee-for-service at public hospitals with the most generous benefit package. <em>Different drug formularies, reimbursement methodologies, and provider-network rules<\/em>.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.05<\/span><span>What does PIC\/S accession mean for Thai pharmaceutical manufacturing?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>Thailand acceded to <strong>the Pharmaceutical Inspection Co-operation Scheme (PIC\/S) in 2016<\/strong>, aligning Thai pharmaceutical GMP with the international PIC\/S guide. <em>Operational implications<\/em>: Thai pharmaceutical manufacturing facilities operate under PIC\/S GMP standards; FDA Thailand inspectors are PIC\/S-recognized. <strong>Export market access<\/strong> is the key benefit \u2014 Thai-manufactured pharmaceuticals with PIC\/S GMP can access PIC\/S Participating Authority markets (Australia, EU member states, Japan, Singapore, Malaysia, US FDA selective recognition) with reduced barriers. <em>For dossier preparation<\/em>: PIC\/S accession supports use of Thai-manufactured pharmaceuticals in international dossier submissions.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.06<\/span><span>How does ICH-GCP affect clinical research in Thailand operationally?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>Thailand operates clinical research under <strong>ICH E6(R2) Good Clinical Practice<\/strong>. <em>Operational implications<\/em>: investigators require ICH-GCP training; sites maintain ICH-GCP-compliant essential documents; sponsors and CROs implement ICH-GCP-aligned monitoring and audit programs. FDA Thailand recognises ICH-GCP and conducts inspections. <strong>Conducting a trial requires two parallel approvals<\/strong>: FDA Thailand IND\/CTA + Ethics Committee approval at each investigator site (Chulalongkorn IRB, Siriraj IRB, Ramathibodi IRB, KKU EC, CMU EC, MoPH Central EC). Thailand-conducted trial data widely accepted by US FDA, EMA, PMDA, Health Canada \u2014 a substantive feature of Thailand&#8217;s regional CRO positioning.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.07<\/span><span>What are the PDPA implications for clinical data and patient records?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>The <strong>Personal Data Protection Act B.E. 2562 (2019)<\/strong> \u2014 operationally effective from June 2022 \u2014 applies to all personal data including clinical research data, patient identifiers, genetic data, biometric data. <em>For hospitals<\/em>: patient consent for processing, data subject rights subject to medical record retention exemption, DPAs with TPAs and insurance partners, cross-border patient transfer documentation. <em>For clinical research<\/em>: informed consent must address PDPA-required rights; DPAs between sponsor, CRO, investigator sites, central labs; cross-border transfer requires legal-basis assessment. Many international sponsors apply EU GDPR \/ US HIPAA \/ Japan APPI compliance frameworks alongside PDPA.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.08<\/span><span>How does HITAP HTA affect pharmaceutical and medical device market access?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p><strong>HITAP (Health Intervention and Technology Assessment Program)<\/strong>, established 2007, conducts HTA for new drug and medical device inclusion in the National List of Essential Medicines (NLEM) and broader public-coverage decisions. <em>HITAP methodology<\/em>: cost-effectiveness analysis, budget impact analysis, equity considerations, ethical evaluation; HITAP&#8217;s methodology is internationally respected. <em>NLEM inclusion is operationally substantive<\/em> \u2014 drugs included on NLEM are reimbursed under the three-scheme coverage framework; non-NLEM drugs may not be reimbursed depending on scheme rules. <strong>HTA submission documentation<\/strong> \u2014 cost-effectiveness model, budget impact analysis, clinical evidence summary, comparator assessment \u2014 sits at procurement-grade translation tier.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.09<\/span><span>What does the 2026 ESG inflection point mean for SET-listed healthcare issuers?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>The 2026 inflection hits SET-listed healthcare issuers \u2014 primarily SERVICE \/ Health Care Services group hospital operators \u2014 with sector-specific materiality. <strong>FTSE Russell ESG Scores replace SET ESG Ratings from 2026<\/strong>; healthcare-sector weightings emphasize <em>access to healthcare, healthcare workforce conditions, supply chain ethics, patient safety, data privacy under PDPA<\/em> alongside the standard governance themes. <strong>ISSB IFRS S2 climate disclosure<\/strong> phases in mandatorily from 2026; hospital groups face substantive Scope 1+2 (energy use) and Scope 3 (medical waste, pharmaceutical supply chain, patient travel) emissions. <em>Draft Climate Change Act<\/em> (Cabinet-approved December 2, 2025; enforcement 2027) creates potential ETS exposure for the largest hospital networks.<\/p><\/div><\/details>\n\n      <details class=\"faq\"><summary><span class=\"faq-num\">Q.10<\/span><span>How is healthcare-sector standards alignment verified for procurement?<\/span><span class=\"faq-icon\">+<\/span><\/summary><div class=\"faq-body\"><p>Three operational verification routes. <strong>Route 01 \u00b7 Standards-body verification<\/strong> \u2014 every standards anchor (ISO 17100, ISO 18841\/20228\/24019, AIIC, PIC\/S GMP via Pharmaceutical Inspection Co-operation Scheme, ICH-GCP via ICH, ISO 13485:2016 via ISO, JCI accreditation via Joint Commission International, MedDRA via MSSO, SNOMED CT via SNOMED International, FTSE Russell, IFRS S1-S2 via ISSB, PDPA B.E. 2562 via PDPC Thailand) is verifiable through the issuing body directly. <strong>Route 02 \u00b7 Reference contacts under mutual NDA<\/strong> \u2014 Pathway 03 provides direct contact with reference contacts at named clients under mutual NDA. <strong>Route 03 \u00b7 Pre-RFP scoping with substantive technical conversation<\/strong> \u2014 Pathway 02 provides a 30-minute call with technical bench input on specific healthcare-sector engagement profiles.<\/p><\/div><\/details>\n    <\/div>\n  <\/div>\n<\/section>\n\n<section id=\"engage\" class=\"engage\">\n  <div class=\"container\">\n    <div class=\"engage-grid\">\n      <div>\n        <div class=\"eyebrow\">Section 10 \u00b7 Engage Othello on healthcare &amp; pharma<\/div>\n        <h2 class=\"engage-h\">Scope a Healthcare &amp; Pharma engagement \u2014<br><em>four pathways.<\/em><\/h2>\n        <p class=\"engage-lead\">All engagement begins with <strong>NDA-from-first-email<\/strong>. Four engagement pathways serve different procurement realities. Pathway 01 returns a 10-component capability brief within 3-5 business days against your RFP; pathway 02 returns a 30-minute scoping call within 2 business days of NDA; pathway 03 returns reference contacts under mutual NDA.<\/p>\n        <div class=\"engage-pathways\">\n          <a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20RFP%20%E2%80%94%20Institutional%20Procurement\" class=\"engage-path\"><div class=\"engage-path-num\">Pathway 01<\/div><div class=\"engage-path-h\">RFP \u00b7 Institutional procurement<\/div><div class=\"engage-path-text\">10-component capability brief \u00b7 3-5 business days \u00b7 against your RFP<\/div><\/a>\n          <a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20Pre-RFP%20Scoping%20Call\" class=\"engage-path\"><div class=\"engage-path-num\">Pathway 02<\/div><div class=\"engage-path-h\">Pre-RFP \u00b7 30-min scoping<\/div><div class=\"engage-path-text\">30-minute call within 2 business days of NDA \u00b7 technical bench input<\/div><\/a>\n          <a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20Procurement%20Reference%20Request\" class=\"engage-path\"><div class=\"engage-path-num\">Pathway 03<\/div><div class=\"engage-path-h\">Reference \u00b7 procurement verification<\/div><div class=\"engage-path-text\">Reference contacts at named clients \u00b7 under mutual NDA<\/div><\/a>\n          <a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20Enquiry\" class=\"engage-path\"><div class=\"engage-path-num\">Pathway 04<\/div><div class=\"engage-path-h\">Media \/ Careers \/ Client support<\/div><div class=\"engage-path-text\">Media enquiry \u00b7 career enquiry \u00b7 existing-client support \u00b7 general<\/div><\/a>\n        <\/div>\n      <\/div>\n      <aside class=\"engage-card\">\n        <div class=\"engage-card-eyebrow\">Engagement desk \u00b7 Bangkok<\/div>\n        <div class=\"engage-contact\">\n          <div class=\"engage-contact-row\"><div class=\"engage-contact-icon\"><svg viewBox=\"0 0 24 24\"><path d=\"M22 16.92v3a2 2 0 0 1-2.18 2 19.79 19.79 0 0 1-8.63-3.07 19.5 19.5 0 0 1-6-6 19.79 19.79 0 0 1-3.07-8.67A2 2 0 0 1 4.11 2h3a2 2 0 0 1 2 1.72 12.84 12.84 0 0 0 .7 2.81 2 2 0 0 1-.45 2.11L8.09 9.91a16 16 0 0 0 6 6l1.27-1.27a2 2 0 0 1 2.11-.45 12.84 12.84 0 0 0 2.81.7A2 2 0 0 1 22 16.92z\"\/><\/svg><\/div><div><div class=\"engage-contact-k\">Phone<\/div><div class=\"engage-contact-v\"><a href=\"tel:+6628592145\">+66 02-859-2145<\/a><\/div><\/div><\/div>\n          <div class=\"engage-contact-row\"><div class=\"engage-contact-icon\"><svg viewBox=\"0 0 24 24\"><path d=\"M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z\"\/><polyline points=\"22,6 12,13 2,6\"\/><\/svg><\/div><div><div class=\"engage-contact-k\">Email \u00b7 NDA from first message<\/div><div class=\"engage-contact-v\"><a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20Engagement%20Enquiry\">info@othelloshop.com<\/a><\/div><\/div><\/div>\n          <div class=\"engage-contact-row\"><div class=\"engage-contact-icon\"><svg viewBox=\"0 0 24 24\"><path d=\"M21 10c0 7-9 13-9 13s-9-6-9-13a9 9 0 0 1 18 0z\"\/><circle cx=\"12\" cy=\"10\" r=\"3\"\/><\/svg><\/div><div><div class=\"engage-contact-k\">Office<\/div><div class=\"engage-contact-v\">Unit 12-03, Chartered Square<br>152 N Sathon Rd, Si Lom, Bang Rak<br>Bangkok 10500, Thailand<\/div><\/div><\/div>\n          <div class=\"engage-contact-row\"><div class=\"engage-contact-icon\"><svg viewBox=\"0 0 24 24\"><circle cx=\"12\" cy=\"12\" r=\"10\"\/><polyline points=\"12 6 12 12 16 14\"\/><\/svg><\/div><div><div class=\"engage-contact-k\">Hours<\/div><div class=\"engage-contact-v\">Mon\u2013Fri 09:00\u201318:00 ICT (GMT+7)<br><span style=\"color:var(--white-mute);font-size:12.5px\">Weekend &amp; after-hours by prior arrangement<\/span><\/div><\/div><\/div>\n        <\/div>\n        <div class=\"engage-cta-row\">\n          <a href=\"mailto:info@othelloshop.com?subject=Healthcare%20%26%20Pharma%20Engagement%20Enquiry\" class=\"btn btn-primary\"><span>Open NDA + Scope<\/span><svg viewBox=\"0 0 24 24\"><path d=\"M5 12h14M13 6l6 6-6 6\"\/><\/svg><\/a>\n          <a href=\"\/contact\/\" class=\"btn btn-ghost\"><span>All contact pathways<\/span><\/a>\n        <\/div>\n      <\/aside>\n    <\/div>\n  <\/div>\n<\/section>\n\n<footer class=\"oth-footer\">\n  <div class=\"container\">\n    <div class=\"oth-footer-grid\">\n      <div>\n        <div class=\"oth-footer-brand-h\">Othello International<\/div>\n        <p class=\"oth-footer-brand-text\">Bangkok-based bilingual technical translation, interpretation, and ESG advisory at institutional procurement tier. Healthcare &amp; Pharma is hub 4 of 8 commercial sub-pages \u2014 anchored to the FDA Thailand \/ MoPH \/ NHSO \/ SSO \/ CSMBS framework, PIC\/S GMP, ICH-GCP, ISO 13485, JCI accreditation, PDPA B.E. 2562.<\/p>\n        <span class=\"oth-footer-tag\">Hub 4 \u00b7 Healthcare &amp; Pharma<\/span>\n      <\/div>\n      <div>\n        <div class=\"oth-footer-col-h\">This page<\/div>\n        <ul class=\"oth-footer-links\">\n          <li><a href=\"#what\">What<\/a><\/li>\n          <li><a href=\"#regulatory\">Regulatory<\/a><\/li>\n          <li><a href=\"#hospitals\">Hospital Groups<\/a><\/li>\n          <li><a href=\"#pharma\">Pharma<\/a><\/li>\n          <li><a href=\"#medical-devices\">Medical Devices<\/a><\/li>\n          <li><a href=\"#clinical\">Clinical Research<\/a><\/li>\n          <li><a href=\"#frameworks\">Frameworks<\/a><\/li>\n          <li><a href=\"#engagement\">Engagement<\/a><\/li>\n          <li><a href=\"#faq\">FAQ<\/a><\/li>\n        <\/ul>\n      <\/div>\n      <div>\n        <div class=\"oth-footer-col-h\">Capabilities<\/div>\n        <ul class=\"oth-footer-links\">\n          <li><a href=\"\/interpretation\/\">Interpretation<\/a><\/li>\n          <li><a href=\"\/technical-translation\/\">Technical Translation<\/a><\/li>\n          <li><a href=\"\/esg-advisory\/\">ESG Advisory<\/a><\/li>\n          <li><a href=\"\/industries\/\">Industries hub<\/a><\/li>\n          <li><a href=\"\/our-team\/\">Our team<\/a><\/li>\n          <li><a href=\"\/our-process\/\">Our process<\/a><\/li>\n        <\/ul>\n      <\/div>\n      <div>\n        <div class=\"oth-footer-col-h\">Engage<\/div>\n        <ul class=\"oth-footer-links\">\n          <li><a href=\"\/contact\/\">Contact<\/a><\/li>\n          <li><a href=\"\/contact\/#pathways\">Engagement pathways<\/a><\/li>\n          <li><a href=\"\/how-we-quote\/\">How we quote<\/a><\/li>\n          <li><a href=\"\/our-clients\/\">Our clients<\/a><\/li>\n          <li><a href=\"\/why-othello\/\">Why Othello<\/a><\/li>\n          <li><a href=\"\/case-studies\/\">Case studies<\/a><\/li>\n        <\/ul>\n      <\/div>\n    <\/div>\n    <div class=\"oth-footer-bottom\">\n      <span>\u00a9 Othello International Co Ltd \u00b7 Bangkok<\/span>\n      <span>FDA Thailand \u00b7 MoPH \u00b7 NHSO \u00b7 SSO \u00b7 CSMBS \u00b7 Drug Act B.E. 2510 \u00b7 Medical Device Act B.E. 2551 \u00b7 PIC\/S \u00b7 ICH-GCP \u00b7 ISO 13485 \u00b7 PDPA B.E. 2562<\/span>\n    <\/div>\n  <\/div>\n<\/footer>\n\n<\/div>\n\n\n<script>\n(function(){\n  var root=document.querySelector('.oth-hp');if(!root)return;\n  var progress=document.getElementById('oth-hp-progress');\n  var stickyNav=document.getElementById('oth-hp-stickynav');\n  var floatCta=document.getElementById('oth-hp-floatcta');\n  var navLinks=stickyNav?stickyNav.querySelectorAll('a[data-target]'):[];\n  var sections=['what','regulatory','hospitals','pharma','medical-devices','clinical','frameworks','engagement','faq'];\n  function onScroll(){\n    var docEl=document.documentElement;\n    var scrollTop=window.pageYOffset||docEl.scrollTop;\n    var scrollHeight=docEl.scrollHeight-docEl.clientHeight;\n    var pct=scrollHeight>0?(scrollTop\/scrollHeight)*100:0;\n    if(progress)progress.style.width=pct+'%';\n    if(stickyNav){if(scrollTop>360)stickyNav.classList.add('visible');else stickyNav.classList.remove('visible');}\n    if(floatCta){if(scrollTop>720&&scrollTop<scrollHeight-600)floatCta.style.display='inline-flex';else floatCta.style.display='none';}\n    if(navLinks.length){\n      var active=null;\n      for(var i=0;i<sections.length;i++){\n        var el=document.getElementById(sections[i]);\n        if(el){var rect=el.getBoundingClientRect();if(rect.top<=140&#038;&#038;rect.bottom>=140){active=sections[i];break;}}\n      }\n      navLinks.forEach(function(a){if(a.getAttribute('data-target')===active)a.classList.add('active');else a.classList.remove('active');});\n    }\n  }\n  window.addEventListener('scroll',onScroll,{passive:true});\n  window.addEventListener('resize',onScroll,{passive:true});\n  onScroll();\n})();\n<\/script>\n\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"Organization\",\n      \"@id\": \"https:\/\/othelloshop.com\/#organization\",\n      \"name\": \"Othello International Co Ltd\",\n      \"alternateName\": \"Othello\",\n      \"url\": \"https:\/\/othelloshop.com\/\",\n      \"telephone\": \"+66-2-859-2145\",\n      \"email\": \"info@othelloshop.com\",\n      \"address\": {\"@type\":\"PostalAddress\",\"streetAddress\":\"Unit 12-03, Chartered Square, 152 N Sathon Rd\",\"addressLocality\":\"Si Lom, Bang Rak\",\"addressRegion\":\"Bangkok\",\"postalCode\":\"10500\",\"addressCountry\":\"TH\"},\n      \"areaServed\": [\"TH\",\"SG\",\"HK\",\"JP\",\"KR\",\"VN\",\"LA\",\"KH\",\"MY\",\"ID\",\"PH\",\"AU\",\"GB\",\"US\",\"DE\",\"FR\",\"CH\"],\n      \"knowsAbout\": [\n        \"Thai Food and Drug Administration (FDA Thailand)\",\n        \"Ministry of Public Health Thailand (MoPH)\",\n        \"National Health Security Office (NHSO)\",\n        \"Social Security Office (SSO)\",\n        \"Comptroller General CSMBS\",\n        \"Drug Act B.E. 2510 (1967) as amended\",\n        \"Medical Device Act B.E. 2551 (2008)\",\n        \"Food Act B.E. 2522\",\n        \"Cosmetic Act B.E. 2558\",\n        \"Health Facility Act B.E. 2541 (1998)\",\n        \"Medical Professions Act B.E. 2525\",\n        \"Pharmacy Profession Act B.E. 2537\",\n        \"Nursing Profession Act B.E. 2528\",\n        \"National Health Security Act B.E. 2545\",\n        \"Social Security Act B.E. 2533\",\n        \"PDPA B.E. 2562 (2019)\",\n        \"PIC\/S accession Thailand 2016\",\n        \"ICH-GCP E6(R2)\",\n        \"ICH-MedDRA\",\n        \"ISO 13485:2016 medical device QMS\",\n        \"ISO 14971 medical device risk\",\n        \"JCI Joint Commission International accreditation\",\n        \"Universal Coverage Scheme (UCS)\",\n        \"Social Security Scheme (SSS)\",\n        \"Civil Servant Medical Benefit Scheme (CSMBS)\",\n        \"National List of Essential Medicines (NLEM)\",\n        \"HITAP Health Intervention and Technology Assessment Program\",\n        \"Bangkok Dusit Medical Services (BDMS)\",\n        \"Bumrungrad International (BH)\",\n        \"Bangkok Chain Hospital (BCH) Kasemrad\",\n        \"Chularat Hospital Group (CHG)\",\n        \"Thonburi Healthcare Group (THG)\",\n        \"Government Pharmaceutical Organisation (GPO)\",\n        \"Mega Lifesciences (MEGA)\",\n        \"EEC medical hub targeted industry\",\n        \"BOI A1+ biotechnology promotion\",\n        \"FTSE Russell ESG Scores healthcare sector\",\n        \"IFRS S1 + S2 climate disclosure\",\n        \"Access to Medicine Index methodology\"\n      ]\n    },\n    {\n      \"@type\": \"BreadcrumbList\",\n      \"@id\": \"https:\/\/othelloshop.com\/industries\/healthcare-pharma\/#breadcrumbs\",\n      \"itemListElement\": [\n        {\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/othelloshop.com\/\"},\n        {\"@type\":\"ListItem\",\"position\":2,\"name\":\"Industries\",\"item\":\"https:\/\/othelloshop.com\/industries\/\"},\n        {\"@type\":\"ListItem\",\"position\":3,\"name\":\"Healthcare & Pharma\",\"item\":\"https:\/\/othelloshop.com\/industries\/healthcare-pharma\/\"}\n      ]\n    },\n    {\n      \"@type\": \"Service\",\n      \"@id\": \"https:\/\/othelloshop.com\/industries\/healthcare-pharma\/#service\",\n      \"name\": \"Healthcare & Pharma \u00b7 Hub 4 sub-page\",\n      \"description\": \"Healthcare & Pharma hub at institutional procurement tier \u2014 bilingual technical translation, interpretation, and ESG advisory anchored to FDA Thailand \/ MoPH \/ NHSO \/ SSO \/ CSMBS architecture, PIC\/S GMP, ICH-GCP, ISO 13485, JCI accreditation, PDPA B.E. 2562, EEC medical hub, and the 2026 ESG inflection point. Four anchored sub-sectors: hospital groups, pharma, medical devices, clinical research.\",\n      \"provider\": {\"@id\":\"https:\/\/othelloshop.com\/#organization\"},\n      \"areaServed\": \"Thailand and cross-border\",\n      \"audience\": {\"@type\":\"Audience\",\"name\":\"SET-listed hospital groups, pharmaceutical companies, medical device companies, CROs, regulatory affairs and clinical operations teams\"},\n      \"hasOfferCatalog\": {\n        \"@type\": \"OfferCatalog\",\n        \"name\": \"Healthcare & Pharma sub-sectors\",\n        \"itemListElement\": [\n          {\"@type\":\"Offer\",\"name\":\"Hospital Groups\",\"description\":\"SET-listed BDMS \u00b7 BH (Bumrungrad) \u00b7 BCH (Kasemrad) \u00b7 CHG \u00b7 RAM \u00b7 THG \u00b7 VIBHA \u00b7 PR9 \u00b7 NTV \u00b7 medical tourism positioning \u00b7 JCI accreditation \u00b7 Health Facility Act B.E. 2541 \u00b7 three-scheme contracting\"},\n          {\"@type\":\"Offer\",\"name\":\"Pharma\",\"description\":\"GPO state \u00b7 Mega Lifesciences (MEGA) \u00b7 Olic \u00b7 domestic generics \u00b7 multinational originator subsidiaries (Pfizer \/ GSK \/ AstraZeneca \/ Roche \/ Novartis \/ Bayer \/ Sanofi \/ MSD \/ Takeda) \u00b7 Drug Act B.E. 2510 \u00b7 PIC\/S GMP since 2016 \u00b7 NLEM \u00b7 HITAP HTA \u00b7 compulsory licensing precedent\"},\n          {\"@type\":\"Offer\",\"name\":\"Medical Devices\",\"description\":\"Medical Device Act B.E. 2551 risk-class I-IV registration \u00b7 ISO 13485:2016 QMS \u00b7 ISO 14971 risk management \u00b7 IMDRF alignment \u00b7 EEC medical hub manufacturing BOI A1+ promotion \u00b7 multinational subsidiaries Medtronic \/ J&J \/ Abbott \/ GE \/ Philips \/ Siemens \/ Stryker\"},\n          {\"@type\":\"Offer\",\"name\":\"Clinical Research\",\"description\":\"Regional CRO hub \u00b7 ICH-GCP E6(R2) \u00b7 FDA Thailand IND\/CTA \u00b7 Ethics Committee approval per site \u00b7 PDPA B.E. 2562 compliance \u00b7 IQVIA \/ Parexel \/ ICON \/ Syneos \/ Labcorp \/ PPD \u00b7 Chulalongkorn \/ Siriraj \/ Ramathibodi \/ KKU \/ CMU investigator sites\"}\n        ]\n      }\n    },\n    {\n      \"@type\": \"FAQPage\",\n      \"@id\": \"https:\/\/othelloshop.com\/industries\/healthcare-pharma\/#faq\",\n      \"mainEntity\": [\n        {\"@type\":\"Question\",\"name\":\"Why does the FDA Thailand \/ MoPH \/ NHSO separation matter for translation accuracy?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Each institution has distinct statutory authorities. Drug registration is under FDA Thailand Drug Control Division (Drug Act B.E. 2510). Hospital licensing is under MoPH Health Facility Act B.E. 2541 administered by HSS. Drug reimbursement under UCS is determined by NHSO + HITAP HTA process. Generalist vendors who conflate these institutions produce documents that read as substantively wrong.\"}},\n        {\"@type\":\"Question\",\"name\":\"What does the Drug Act B.E. 2510 registration regime look like for pharmaceuticals?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Drug Act B.E. 2510 (1967, as amended) establishes modern drugs (originator, generic, biosimilar), traditional Thai medicine, herbal medicine categories. Registration with FDA Thailand Drug Control Division requires CMC, pre-clinical and clinical data for NCEs, bioequivalence data for generics, stability data, labeling. Originator registration may follow streamlined pathways if approved by US FDA, EMA, PMDA, Health Canada. Compulsory licensing under Patent Act B.E. 2522 has historical precedent for HIV, cardiovascular, oncology drugs.\"}},\n        {\"@type\":\"Question\",\"name\":\"How does the Medical Device Act B.E. 2551 risk-class system work?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Medical Device Act B.E. 2551 (2008) introduced risk-based class I-IV classification aligned with IMDRF practice. Class I (low risk) with notification; Class II (low-moderate) with declaration; Class III (moderate-high) with full registration including technical file; Class IV (high risk) with comprehensive registration including clinical data. ISO 13485:2016 QMS underpins manufacturer quality.\"}},\n        {\"@type\":\"Question\",\"name\":\"How do the three coverage schemes UCS \/ SSS \/ CSMBS operationally differ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"UCS administered by NHSO since 2002 under National Health Security Act B.E. 2545 covers ~70% of population with capitation-based payment. SSS administered by SSO under Social Security Act B.E. 2533 covers ~20% of population with tripartite financing. CSMBS administered by Comptroller General's Department covers ~9% of population with fee-for-service. Different drug formularies, reimbursement methodologies, provider-network rules.\"}},\n        {\"@type\":\"Question\",\"name\":\"What does PIC\/S accession mean for Thai pharmaceutical manufacturing?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Thailand acceded to PIC\/S in 2016, aligning Thai pharmaceutical GMP with the international PIC\/S guide. Thai pharmaceutical manufacturing facilities operate under PIC\/S GMP standards; FDA Thailand inspectors are PIC\/S-recognized. Export market access is the key benefit \u2014 Thai-manufactured pharmaceuticals can access PIC\/S Participating Authority markets (Australia, EU, Japan, Singapore, Malaysia, US FDA selective recognition) with reduced barriers.\"}},\n        {\"@type\":\"Question\",\"name\":\"How does ICH-GCP affect clinical research in Thailand operationally?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Thailand operates clinical research under ICH E6(R2) Good Clinical Practice. Conducting a trial requires two parallel approvals: FDA Thailand IND\/CTA and Ethics Committee approval at each investigator site (Chulalongkorn IRB, Siriraj IRB, Ramathibodi IRB, KKU EC, CMU EC, MoPH Central EC). Thailand-conducted trial data widely accepted by US FDA, EMA, PMDA, Health Canada.\"}},\n        {\"@type\":\"Question\",\"name\":\"What are the PDPA implications for clinical data and patient records?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PDPA B.E. 2562 (2019) applies to all personal data including clinical research data, patient identifiers, genetic data, biometric data. Hospitals require patient consent, data subject rights with medical record retention exemption, DPAs with TPAs and insurance partners. Clinical research requires informed consent addressing PDPA rights, DPAs between sponsor \/ CRO \/ sites \/ labs, cross-border data transfer legal-basis assessment.\"}},\n        {\"@type\":\"Question\",\"name\":\"How does HITAP HTA affect pharmaceutical and medical device market access?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"HITAP conducts health technology assessment for new drug and medical device inclusion in the NLEM. HITAP methodology includes cost-effectiveness analysis, budget impact analysis, equity considerations. NLEM inclusion is operationally substantive \u2014 drugs included on NLEM are reimbursed under the three-scheme framework; non-NLEM drugs may not be reimbursed depending on scheme rules.\"}},\n        {\"@type\":\"Question\",\"name\":\"What does the 2026 ESG inflection point mean for SET-listed healthcare issuers?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"FTSE Russell ESG Scores replace SET ESG Ratings from 2026. Healthcare-sector weightings emphasize access to healthcare, healthcare workforce conditions, supply chain ethics, patient safety, data privacy under PDPA. ISSB IFRS S2 climate disclosure phases in mandatorily from 2026; hospital groups face substantive Scope 1+2 and Scope 3 emissions. Draft Climate Change Act creates potential ETS exposure for the largest hospital networks.\"}},\n        {\"@type\":\"Question\",\"name\":\"How is healthcare-sector standards alignment verified for procurement?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Three routes. Route 01 \u2014 every standards anchor (ISO 17100, ISO 18841\/20228\/24019, AIIC, PIC\/S GMP, ICH-GCP, ISO 13485:2016, JCI, MedDRA, SNOMED CT, FTSE Russell, IFRS S1-S2, PDPA B.E. 2562) is verifiable through the issuing body directly. Route 02 \u2014 Pathway 03 provides reference contacts at named clients under mutual NDA. Route 03 \u2014 Pathway 02 provides 30-minute pre-RFP scoping with technical bench input.\"}}\n      ]\n    }\n  ]\n}\n<\/script>\n\n\n\n<!-- othello-seo:cluster-links -->\n<h2>Related industries services<\/h2>\n<ul>\n  <li><a href=\"https:\/\/www.othellointernational.com\/industries\/\">Industries<\/a><\/li>\n  <li><a href=\"https:\/\/www.othellointernational.com\/energy-utilities-2\/\">Energy &#038; Utilities<\/a><\/li>\n  <li><a href=\"https:\/\/www.othellointernational.com\/government-rfp\/\">GOVERNMENT &#038; RFP<\/a><\/li>\n  <li><a href=\"https:\/\/www.othellointernational.com\/esia-infrastructure\/\">ESIA &#038; Infrastructure<\/a><\/li>\n  <li><a href=\"https:\/\/www.othellointernational.com\/real-estate-reits\/\">Real Estate &#038; REITs<\/a><\/li>\n  <li><a href=\"https:\/\/www.othellointernational.com\/tech-telecoms\/\">Tech &#038; Telecoms<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>On this page What Regulatory Hospitals Pharma Med Devices Clinical Frameworks Engagement FAQ Engage Engage \u2192 Healthcare &amp; Pharma \u00b7 FDA Thailand \u00b7 MoPH \u00b7 Drug Act B.E. 2510 \u00b7 Medical Device Act B.E. 2551 Hub 4 of 8 Bangkok \u00b7 GMT+7 In-house bench Home \u203a Industries \u203a Healthcare &amp; Pharma Healthcare &amp; Pharma \u00b7 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_yoast_wpseo_title":"Healthcare & Pharma Translation Thailand | Othello","_yoast_wpseo_metadesc":"Thai\u2013English medical, pharma and life-sciences translation \u2014 clinical, Thai FDA regulatory and patient documents with precise terminology. ISO 17100.","_yoast_wpseo_focuskw":"healthcare and pharma","_yoast_wpseo_canonical":"","rank_math_title":"Healthcare & Pharma Translation Thailand | Othello","rank_math_description":"Thai\u2013English medical, pharma and life-sciences translation \u2014 clinical, Thai FDA regulatory and patient documents with precise terminology. ISO 17100.","rank_math_focus_keyword":"healthcare and pharma","rank_math_canonical_url":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_yoast_wpseo_twitter-title":"","_yoast_wpseo_twitter-description":"","footnotes":"","rank_math_robots":["index"]},"class_list":["post-30657","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/pages\/30657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/comments?post=30657"}],"version-history":[{"count":3,"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/pages\/30657\/revisions"}],"predecessor-version":[{"id":31454,"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/pages\/30657\/revisions\/31454"}],"wp:attachment":[{"href":"https:\/\/www.othellointernational.com\/th\/wp-json\/wp\/v2\/media?parent=30657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}